2023-12-12T00:18:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-5-dibromopyridine-cas-625-92-3.html 2023-12-12T00:18:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-methylamino-pyridine-3-methanol-cas-32399-12.html 2023-12-12T00:18:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/trans-4-aminocyclohexanol-cas-27489-62-9.html 2024-12-12T22:09:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/pevonedistat-cas-905579-51-3.html 2024-12-12T22:09:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/milvexian-cas-1802425-99-5.html 2023-12-12T00:18:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/ixazomib-cas-1072833-77-2.html 2024-12-12T22:09:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/pirtobrutinib-cas-2101700-15-4.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/heparin-sodium-cas-9041-08-1.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/samuraciclib-cas-1805833-75-3.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-bromo-5-fluoropyridine-4-carboxylic-acid.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-chloro-4-iodopyridin-2-amine-cas-1152617-24.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/methyl-6-fluoro-5-methylpyridine-3.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-6-bromo-3-fluoropyridin-2-yl-ethan-1-one.html 2023-12-12T00:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/deutivacaftor-cas-1413431-07-8.html 2024-12-12T22:09:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/12112-bemcentinib-cas-1037624-75-1.html 2023-12-12T00:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-hydroxypyridine-cas-626-64-2.html 2023-12-12T00:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/lithocholic-acid-glycine-cas-474-74-8.html 2023-12-12T00:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/bilirubin-cas-635-65-4.html 2023-12-12T00:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/vidofludimus-cas-717824-30-1.html 2023-12-12T00:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hyocholic-acid-cas-547-75-1.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/suzetrigine-vx-548-cas-2649467-58-1.html 2023-12-12T00:18:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-chloro-3-pyridinecarboxaldehyde-cas-36404.html 2023-12-12T00:18:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-3-methylphenyl-amino-3-pyridinesulfonamide.html 2023-12-12T00:18:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-acetyl-2-bromopyridine-cas139042-59-4.html 2023-12-12T00:18:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/methyl-2-bromo-5-fluoropyridine-4-carboxylate.html 2023-12-12T00:18:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hyodeoxycholic-acid-cas-83-49-8.html 2024-12-12T22:09:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/orforglipron-cas-2212020-52-3.html 2023-12-12T00:42:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/nonapeptide-1-cas-158563-45-2.html 2023-12-12T00:42:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/6-6-dimethyl-3-azabicyclo-3-1-0-hexane.html 2023-12-12T00:42:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-2-bromo-1-oxopropyl-spiro-2h-1-3.html 2023-12-12T00:42:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-2-3-dimethylphenyl-ethyl-chloride-cas-60907.html 2023-12-12T00:42:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-4-ethylphenyl-2-methylpropanoic-acid-cas.html 2023-12-12T00:42:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-chloromethyl-5-methylpyridine-hcl-cas.html 2023-12-12T01:05:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/7-chlorothieno-3-2-b-pyridine-cas-69627-03-8.html 2024-04-14T02:52:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycohyodeoxycholic-acid-cas-13042-33-6.html 2024-04-14T02:52:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycodehydrocholic-acid-cas-3415-45-0.html 2024-04-14T02:52:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycodeoxycholic-acid-sodium-cas-16409-34-0.html 2024-04-14T02:52:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycohyodeoxycholic-acid-sodium-salt-ghdca.html 2024-12-12T22:09:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycolithocholic-acid-sodium-salt-cas-24404.html 2024-04-14T02:52:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3h-sodium-glycoursodeoxycholate-cas-92411-07.html 2024-12-12T22:09:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycocholic-acid-sodium-salt-cas-863-57-0.html 2024-12-12T22:09:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycochenodeoxycholic-acid-sodium-salt-cas.html 2024-12-12T22:09:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycocholic-acid-cas-475-31-0.html 2024-04-14T02:53:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycodeoxycholic-acid-cas-360-65-6.html 2024-04-14T02:53:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycoursodeoxycholic-acid-cas-64480-66-6.html 2024-12-12T22:09:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurohyodeoxycholic-acid-sodium-salt-hydrate.html 2024-12-12T22:09:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sodium-cholate-cas-361-09-1.html 2024-12-12T22:09:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurolithocholic-acid-sodium-salt-cas-6042-32.html 2024-04-14T02:53:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycochenodeoxycholic-acid-cas-640-79-9.html 2024-04-14T02:53:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/lithocholic-acid-cas-434-13-9.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurohyodeoxycholic-acid-sodium-hydrate-cas.html 2024-04-14T02:53:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurodeoxychloic-acid-cas-516-50-7.html 2024-04-14T02:53:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurodehydrocholate-cas-517-37-3.html 2024-04-14T02:53:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurochenodeoxycholic-acid-cas-516-35-8.html 2024-04-14T02:53:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sodium-taurodeoxycholate-hydrate-cas-207737.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurocholate-cas-81-24-3.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/deoxycholic-acid-cas-83-44-3.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurocholic-acid-sodium-salt-hydrate-cas.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dehydrocholic-acid-cas-81-23-2.html 2024-12-12T22:09:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-alpha-hydroxy-laxogenin-cas-56786-63-1.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sodium-tauroursodesoxycholate-cas-35807-85-3.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurochenodeoxycholic-acid-sodium-salt-cas.html 2024-04-14T02:53:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sodium-deoxycholate-cas-302-95-4.html 2024-04-14T02:53:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/trifluoroacetic-anhydride-cas-407-25-0.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/aprotinin-cas-9087-70-1.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/polyinosinic-polycytidylic-acid-potassium.html 2024-04-14T02:53:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/cholesterol-cas-57-88-5.html 2024-04-14T02:53:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/cytidine-5-triphosphate-trisodium-salt-cas.html 2024-04-14T02:53:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/adenosine-5-diphosphoglucose-disodium-salt.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/guanosine-3-5-cyclic-monophosphate-cas-7665.html 2024-04-14T02:53:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyguanosine-5-triphosphate-trisodium.html 2024-12-12T22:09:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyuridine-5-triphosphate-trisodium-cas.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyadenosine-5-triphosphate-disodium-cas.html 2024-04-14T02:53:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-thymidine-5-monophosphate-disodium-salt-cas.html 2024-04-14T02:53:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/trifluoroacetic-acid-cas-76-05-1.html 2024-04-14T02:53:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/uridine-5-triphosphate-diaodium-salt-cas.html 2024-04-14T02:53:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyuridine-5-monophosphate-disodium-salt.html 2024-04-14T02:53:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/taurodeoxycholic-acid-sodium-salt-cas-1180-95.html 2024-04-14T02:53:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/7-dehydrocholesterol-cas-434-16-2.html 2024-04-14T02:53:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/guanosine-5-diphosphoglucose-disodium-salt.html 2024-12-12T22:09:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/inosine-5-triphosphate-disodium-salt-cas.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/polyadenosinic-acid-potassium-salt-cas-26763.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/cytidine-5-diphosphoglucose-disodium-salt-cas.html 2024-04-14T02:53:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/lanosterol-cas-79-63-0.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxycytidine-5-diphosphate-disodium-salt.html 2024-04-14T02:53:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/adenosine-5-diphosphate-cas-58-64-0.html 2024-04-14T02:53:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/guanosine-5-diphosphate-disodium-salt-cas.html 2024-04-14T02:53:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/n1-methylpseudouridine-5-triphosphate-sodium.html 2024-04-14T02:53:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyadenosine-5-diphosphate-disodium-salt.html 2024-12-12T22:09:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/adenosine-5-diphosphate-monopotassium-salt.html 2024-04-14T02:53:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyguanosine-5-diphosphate-disodium-salt.html 2024-04-14T02:53:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxythymidine-5-diphosphate-trisodium-salt.html 2024-04-14T02:53:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyuridine-5-diphosphate-disodium-salt.html 2024-12-12T22:09:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyadenosine-5-monophosphate-cas-220203.html 2024-04-14T02:53:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/adenosine-5-triphosphate-cas-56-65-5.html 2024-04-14T02:53:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/ethyl-6-8-dichlorooctanoate-cas-1070-64-0.html 2024-04-14T02:53:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glycine-methyl-ester-hydrochloride-cas-5680.html 2024-04-14T02:53:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sodium-taurocholate-cas-145-42-6.html 2024-04-14T02:53:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/o-7-azabenzotriazol-1-yl-uronium-hexafluoro.html 2024-04-14T02:53:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-bromo-3-methoxypropane-cas-36865-41-5.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyguanosine-5-monophosphate-disodium.html 2024-04-14T02:53:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/methyl-4-acetylamino-3-bromo-2-2-bromoethoxy.html 2024-04-14T02:53:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/6-iodo-1h-indazole-cas-261953-36-0.html 2024-04-14T02:53:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-2-cyclohexanedione-cas-765-87-7.html 2024-04-14T02:53:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-4-dichloro-5-methoxyaniline-cas-98446-49-2.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxythymidine-5-triphosphate-trisodium-cas.html 2024-04-14T02:53:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/piperazine-anhydrous-cas-110-85-0.html 2024-04-14T02:53:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-acetoxystyrene-cas-2628-16-2.html 2024-04-14T02:53:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/semaglutide-cas-99291-20-0.html 2024-12-12T22:09:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxycytidine-5-monophosphate-disodium-salt.html 2024-04-14T02:53:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxycytidine-5-monophosphate-cas-1032-65-1.html 2024-04-14T02:53:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-chloromethyl-4-fluoro-1-4-diazoniabicyclo-2.html 2024-04-14T02:53:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-5-dichloro-2-pyridinecarboxylic-acid-cas.html 2024-12-12T22:09:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-benzofurazancarboxaldehyde-cas-32863-32-4.html 2024-04-14T02:53:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/triethylenetetraminetetrahydrochloride-cas.html 2024-12-12T22:09:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sevelamer-carbonate-cas-845273-93-0.html 2024-04-14T02:53:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-chloro-3-pyridin-2-yl-aniline-cas-879088-41.html 2024-04-14T02:53:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/creatine-monohydrate-cas-6020-87-7.html 2024-04-14T02:53:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/2-deoxyadenosine-5-monophosphate-disodium-sa.html 2024-04-14T02:53:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/capivasertib-cas-1143532-39-1.html 2024-04-14T02:53:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/allochenodeoxycholic-acid-cas-15357-34-3.html 2024-04-14T02:53:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/salcaprozate-sodium-cas-203787-91-1.html 2024-04-14T02:53:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-bromo-3-nitropyridine-2-carbonitrile-cas.html 2024-04-14T02:53:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/acoramidis-cas-1446711-81-4.html 2024-04-14T02:53:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/tirzepatide-cas-2023788-19-2.html 2024-04-14T02:53:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-3-5-difluorophenoxy-propanenitrile-cas.html 2024-04-14T02:53:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-7-difluorochroman-4-one-cas-844648-22-2.html 2024-04-14T02:53:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/methyl-4-amino-3-bromo-5.html 2024-12-12T22:09:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/7-bromo-2-methyl-1h-benzoimidazole-5.html 2024-12-12T22:09:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/adenosine-5-diphosphate-trilithium-salt-cas.html 2024-12-12T22:09:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1h-benzimidazole1h-benzimidazole-5.html 2024-12-12T22:09:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/coenzymes-and-nucleotides-series/adenosine-5-monophosphate-monosodium-salt-cas.html 2024-04-14T02:53:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/tegoprazan-cas-942195-55-3.html 2024-04-14T02:53:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/s-5-7-difluorochroman-4-ol-cas-942195-91-7.html 2024-04-14T02:53:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/birinapant-cas-1629229-37-3.html 2024-04-14T02:53:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/n-1-3-dimethylbutylidene-3-hydroxy-2.html 2024-04-14T02:53:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-pyrenol-cas-5315-79-7.html 2024-04-14T03:19:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-propiothetin-hydrochlorid-cas-4337.html 2024-04-14T03:19:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sodium-dehydrocholate-cas-145-41-5.html 2024-04-14T03:19:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-chloro-2-fluoroaniline-cas-2106-04-9.html 2024-07-18T19:47:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/lappaconitine-hydrobromide-cas-97792-45-5.html 2024-12-12T22:09:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/baricitinib-cas-1187594-09-7.html 2024-09-12T19:25:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/3-morpholinopropanesulfonic-acid-cas-1132-61.html 2024-09-12T19:25:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/4-morpholineethanesulfonic-acid-cas-4432-31-9.html 2024-09-12T19:25:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/n-ethylcarbazole-cas-86-28-2.html 2024-09-12T19:25:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/chaps-cas-75621-03-3.html 2024-09-12T19:25:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/tris-2-carboxyethyl-phosphine-hydrochloride.html 2024-09-12T19:25:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/bis-tris-propane-cas-64431-96-5.html 2024-09-12T19:25:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-2-3-4-tetrahydrocarbazole-cas-942-01-8.html 2024-09-12T19:25:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/s-2-methylproline-hydrochloride-cas-1508261.html 2024-09-12T19:25:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/n-propylcarbazole-cas-1484-10-2.html 2024-09-12T19:25:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/hepes-cas-7365-45-9.html 2024-09-12T19:25:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/9-acetylcarbazole-cas-574-39-0.html 2024-12-12T22:09:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-6-bis-n-n-dibenzylthiocarbamoyldithio.html 2024-09-12T19:25:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/dl-dithiothreitol-cas-3483-12-3.html 2024-09-12T19:25:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/thiamidol-cas-1428450-95-6.html 2024-09-12T19:25:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/carbazole-cas-86-74-8.html 2024-09-12T19:25:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/tricine-5704-04-1.html 2024-09-12T19:25:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3alpha-hydroxy-5beta-cholan-24-oic-acid-3.html 2024-09-12T19:25:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/taps-cas-29915-38-6.html 2024-09-12T19:25:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-lys-boc-isopropyl-oh-cas-201003-48-7.html 2024-09-12T19:25:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/danicopan-cas-1903768-17-1.html 2024-09-12T19:25:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/carbazole-9-ethanol-cas-1484-14-6.html 2024-09-12T19:25:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/fine-chemicals/sodium-hexamethylene-1-6-bisthiosulfate.html 2024-09-12T19:25:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/adagrasib-cas-2326521-71-3.html 2024-09-12T19:25:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/fine-chemicals/isophthalic-dihydrazide-dc02-cas-2760-98-7.html 2024-09-12T19:25:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/aprocitentan-cas-1103522-45-7.html 2024-12-12T22:09:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/iptacopan-cas-1644670-37-0.html 2024-09-12T19:25:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/survodutide-cas-2805997-46-8.html 2024-09-12T19:25:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-3-4-6-tri-o-acetyl-2-acetylamido-2-deoxy-b.html 2024-09-12T19:25:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/repotrectinib-cas-1802220-02-5.html 2024-09-12T19:25:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/vitamin-d3-cas-67-97-0.html 2024-09-12T19:25:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/crotonic-acid-cas-107-93-7.html 2024-09-12T19:25:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/gepotidacin-cas-1075236-89-3.html 2024-09-12T19:25:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sisomicin-sulfate-cas-53179-09-2.html 2024-09-12T19:25:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/r-3-methylpiperazin-2-one-cas-922178-61-8.html 2024-09-12T19:25:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fruquintinib-cas-1194506-26-7.html 2024-09-12T19:25:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/carboplatin-cas-41575-94-4.html 2024-12-12T22:09:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/elinzanetant-cas-929046-33-3.html 2024-09-12T19:25:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/keratin-cas-68238-35-7.html 2024-09-12T19:25:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/glucosamine-cas-3416-24-8.html 2024-09-12T19:25:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/metadoxine-cas-74536-44-0.html 2024-09-12T19:25:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/7-amino-3-1-methyl-5-tetrazolylthio-methyl-3.html 2024-09-12T19:25:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/cisplatin-cas-15663-27-1.html 2024-09-12T19:25:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3r-5s-5-bis-4-methoxyphenyl-phenyl-methoxy.html 2024-09-12T19:25:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/netilmicin-sulfate-cas-56391-57-2.html 2024-09-12T19:25:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/eteplirsen-cas-1173755-55-9.html 2024-09-12T19:25:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/trofinetide-cas-853400-76-7.html 2024-09-12T19:25:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/sisomicin-base-cas-32385-11-8.html 2024-09-12T19:25:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/pimicotinib-cas-2253123-16-7.html 2024-09-12T19:54:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/buffer/sodium-2-chloroethanesulfonate-monohydrate.html 2026-02-10T20:41:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1r-2r-1-2-diaminocyclohexane-acid-cas-20439.html 2026-02-10T20:41:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-chloro-6-6-dimethyl-2-heptyene-4-alkyne-cas.html 2026-02-10T20:41:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/cis-octahydro-1h-isoindole-hydrochloride-cas.html 2026-02-10T20:41:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-benzylacrylicacid-cas-5669-19-2.html 2026-02-10T20:41:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-methylpropanedioic-acid-cas-516-05-2.html 2026-02-10T20:41:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-4-bromo-3-tetrahydro-2h-pyran-2-yl-oxy.html 2026-02-10T20:42:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-nitro-2-propylthio-pyrimdine-4-6-diol-cas.html 2026-02-10T20:42:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-methylindole-cas-603-76-9.html 2026-02-10T20:42:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/ethyl-n-benzyl-3-oxo-4-piperidine-carboxylate.html 2026-02-10T20:42:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/s-oxetan-2-ylmethanamine-cas-2091328-57-1.html 2026-02-10T20:42:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-d-phe-4-nhboc-oh-cas-214750-77-3.html 2026-02-10T20:42:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-4-bromo-3-formylphenoxy-benzonitrile-cas.html 2026-02-10T20:42:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/riociguat-cas-625115-55-1.html 2026-02-10T20:42:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/racecadotril-cas-81110-73-8.html 2026-02-10T20:42:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-2-chloro-4-cyclopentylamino-5-pyrimidinyl-2.html 2026-02-10T20:42:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hexadecanedioic-acid-1-methyl-ester-cas-18451.html 2026-02-10T20:42:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/o-benzylhydroxylamine-hydrochloride-cas-2687.html 2026-02-10T20:42:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-14-dibromotetradecane-37688-96-3.html 2026-02-10T20:42:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/thioanisole-cas100-68-5.html 2026-02-10T20:42:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-4-5-trichloropyrimidine-cas-5750-76-5.html 2026-02-10T20:42:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/euk-134-cas-81065-76-1.html 2026-02-10T20:42:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/ceramides-cas-100403-19-8.html 2026-02-10T20:42:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/l-homoserine-cas-672-15-1.html 2026-02-10T20:42:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/benzenamine-2-1-methylethyl-thio.html 2026-02-10T20:42:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-3-2-naphthyl-d-alanine-cas-138774-94-4.html 2026-02-10T20:42:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/palmitoyl-tetrapeptide-7-cas-221227-05-0.html 2026-02-10T20:42:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/carcinine-dihydrochloride-57022-38-5.html 2026-02-10T20:42:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-butylresorcinol-18979-61-8.html 2026-02-10T20:42:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-5-diaminopentane-dihydrochloride-cas1476-39.html 2026-02-10T20:42:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-4-dichloropyrimidine-cas-3934-20-1.html 2026-02-10T20:42:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/palmitic-acid-cas-57-10-3.html 2026-02-10T20:42:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-beta-alanine-cas-3303-84-2.html 2026-02-10T20:42:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/c20-otbu-glu-otbu-aeea-aeea-oh-cas1188328-37.html 2026-02-10T20:42:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-4-amino-d-phenylalanine-324017-21-2.html 2026-02-10T20:42:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/vitamin-a-palmitate-79-81-2.html 2026-02-10T20:42:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-14-tetradecanediol-19812-64-7.html 2026-02-10T20:42:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/15-tert-butoxy-15-oxopentadecanoic-acid-cas.html 2026-02-10T20:42:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/heptadecanedioic-acid-mono-tert-butyl-ester.html 2026-02-10T20:42:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-his-trt-aib-glu-otbu-gly-oh-cas-1890228.html 2026-02-10T20:42:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/14-tert-butoxy-14-oxotetradecanoic-acid.html 2026-02-10T20:42:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-nh-peg2-ch2cooh-cas108466-89-3.html 2026-02-10T20:42:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-4-amino-l-phenylalanine-cas-95753-56-3.html 2026-02-10T20:42:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/17-amino-10-oxo-3-6-12-15-tetraoxa-9.html 2026-02-10T20:42:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-2-2-aminoethoxy-ethoxy-acetic-acid.html 2026-02-10T20:42:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-2-2-aminoethoxy-ethoxy-acetic-acid-cas.html 2026-02-10T20:42:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-8-amino-3-6-dioxaoctanoic-acid-dcha.html 2026-02-10T20:42:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/octadecanedioic-acid-mono-tert-butyl-ester.html 2026-02-10T20:42:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-2-fmoc-amino-ethoxy-ethoxy-acetic-acid-cas.html 2026-02-10T20:42:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/retinyl-propionate-7069-42-3.html 2026-02-10T20:42:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/20-tert-butoxy-20-oxoicosanoic-acid-cas.html 2026-02-10T20:42:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-18-octadecanedioic-acid-cas-871-70-5.html 2026-02-10T20:42:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-aph-l-hor-oh-cas-1253282-31-3.html 2026-02-10T20:42:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/pal-glu-osu-obn-cas-294855-89-3.html 2026-02-10T20:42:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-glu-ome-cas-6384-08-3.html 2026-02-10T20:42:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-d-aph-cbm-oh-cas-324017-22-3.html 2026-02-10T20:42:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/pal-glu-osu-oh-cas-294855-91-7.html 2026-02-10T20:42:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/filgotinib-glpg-0634-cas-1206161-97-8.html 2026-02-10T20:42:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/filgotinib-maleate-cas-1802998-75-9.html 2026-02-10T20:42:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/l-4-5-dihydroorotic-acid-cas-5988-19-2.html 2026-02-10T20:42:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5-bromo-1-2-4-triazolo-1-5-a-pyridin-2-amine.html 2026-02-10T20:42:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/pal-glu-osu-ome-cas-294855-90-6.html 2026-02-10T20:42:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/3-amino-2-bromo-4-picoline-cas-126325-50-6.html 2026-02-10T20:42:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-tridecanedioate-cas-1472-87-3.html 2026-02-10T20:42:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/palmitoyl-pentapeptide-214047-00-4.html 2026-02-10T20:44:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-tetradecanedioate-cas-5024-21-5.html 2026-02-10T20:46:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-his-trt-aib-glu-otbu-gly-oh-cas-1169630.html 2026-02-10T20:46:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/otbu-hexadecadioyl-l-glu-osu-otbu-cas-843666.html 2026-02-10T20:46:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/l-glutamic-acid-1-benzyl-ester-cas-13030-09-6.html 2026-02-10T20:46:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-his-trt-aib-oh-cas-2061897-68-3.html 2026-02-10T20:46:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/octa-otbu-glu-aeea-aeea-oh-otbu-cas-1118767.html 2026-02-10T20:48:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-hexadecanedioate-cas-19102-90-0.html 2026-02-10T21:21:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/nusinersen-cas-1258984-36-9.html 2026-02-10T21:21:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-dab-boc-oh-cas-125238-99-5.html 2026-02-10T21:21:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/potassium-trifluoro-2-fluoro-6-hydroxyphenyl.html 2026-02-10T21:21:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dl-a-hydroxystearic-acid-cas-629-22-1.html 2026-02-10T21:21:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-fluoro-6-hydroxyphenylboronic-acid-cas.html 2026-02-10T21:01:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hyaluronic-acid-cas-9004-61-9.html 2026-02-10T21:21:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-chloro-7-cyclopentyl-7h-pyrrolo-2-3-d.html 2026-02-10T21:21:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-asn-trt-oh-cas-132388-59-1.html 2026-02-10T21:21:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dipeptide-diaminobutyroyl-benzylamide.html 2026-02-10T21:21:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-1-oxotetradecyl-oxy-2-5-pyrrolidinedione.html 2026-02-10T21:21:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-cys-trt-oh-cas-103213-32-7.html 2026-02-10T21:21:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/5s-6s-9r-5-amino-6-2-3difluorophenyl-6-7-8-9.html 2026-02-10T21:21:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-d-aph-tbu-cbm-oh-cas-1433975-21-3.html 2026-02-10T21:21:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-dodecanedioate-cas-1731-79-9.html 2026-02-10T21:21:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/d-hydroorotic-acid-cas-5988-53-4.html 2026-02-10T21:21:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hexadecanedioic-acid-cas-505-54-4.html 2026-02-10T21:21:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-6-dichloro-5-fluoronicotinamide-cas-113237.html 2026-02-10T21:21:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-pentadecanedioate-cas-36575-82-3.html 2026-02-10T21:21:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/s-pro-xylane-cas-868156-46-1.html 2026-02-10T21:21:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hydroxypinacolone-retinoate-cas-893412-73-2.html 2026-02-10T21:22:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/dimethyl-octadecanedioate-cas-1472-93-1.html 2026-02-10T21:21:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-glu-otbu-cas-45120-30-7.html 2026-02-10T21:21:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/semaglutide-main-chain-p29-cas-1169630-82-3.html 2026-02-10T21:21:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/octadecanedioic-acid-monobenzyl-ester-cas.html 2026-02-10T21:21:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/l-ergothioneine-cas-497-30-3.html 2026-02-10T21:22:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-gly-gly-oh-cas-35665-38-4.html 2026-02-10T21:21:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/cbz-pro-pro-oh-cas-7360-23-8.html 2026-02-10T21:22:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-gly-gly-gly-oh-cas-170941-79-4.html 2026-02-10T21:22:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-met-oh-cas-71989-28-1.html 2026-02-10T21:21:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-his-trt-oh-cas-109425-51-6.html 2026-02-10T21:22:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-dap-z-oh-cas-65710-57-8.html 2026-02-10T21:21:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-asp-otbu-oh-cas-3057-74-7.html 2026-02-10T21:22:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-ser-tbu-nh2-hcl-cas-323587-47-9.html 2026-02-10T21:22:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-gly-pro-oh-cas-212651-48-4.html 2026-02-10T21:22:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-lys-ivdde-oh-cas-862847-44-7.html 2026-02-10T21:22:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/n6-cbz-l-lysine-cas-1155-64-2.html 2026-02-10T21:22:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-d-arg-hcl-h2o-cas-113712-06-4.html 2026-02-10T21:22:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-d-arg-hcl-cas-35897-34-8.html 2026-02-10T21:21:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/thiomorpholine1-1-dioxide-hydrochloride-cas.html 2026-02-10T21:22:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-lys-boc-oh-cas-2418-95-3.html 2026-02-10T21:21:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-l-pyroglutamic-acid-methyl-ester-cas.html 2026-02-10T21:21:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/l-glutamic-acid-5-methyl-ester-cas-1499-55-4.html 2026-02-10T21:21:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/2-2-chloroethoxy-ethanol-cas-628-89-7.html 2026-02-10T21:21:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/n-5-bromo-1-2-4-triazolo-1-5-a-pyridin-2-yl.html 2026-02-10T21:21:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/hexadecanedioic-acid-mono-tert-butyl-ester.html 2026-02-10T21:21:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-ile-aib-oh-cas-2171139-20-9.html 2026-02-10T21:21:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/cbz-gln-trt-oh-cas-132388-60-4.html 2026-02-10T21:21:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/linoleic-acid-cas-60-33-3.html 2026-02-10T21:21:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/4-4-4-4-5-5-tetramethyl-1-3-2-cas-1092563-25.html 2026-02-10T21:21:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/1-5-diaminopentane-cas-462-94-2.html 2026-02-10T21:21:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/eicosanedioic-acid-cas-2424-92-2.html 2026-02-10T21:21:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-pro-pro-oh-cas-129223-22-9.html 2026-02-10T21:22:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-gln-oh-cas-71989-20-3.html 2026-02-10T21:22:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-l-lys-dde-oh-cas-444795-66-8.html 2026-02-10T21:21:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/16-benzyloxy-16-oxohexadecanoic-acid-cas.html 2026-02-10T21:21:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-lys-boc-oh-cas-71989-26-9.html 2026-02-10T21:22:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-thr-tbu-oh-cas-4378-13-6.html 2026-02-10T21:22:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-l-lys-z-oh-cas-2389-45-9.html 2026-02-10T21:21:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-gln-trt-oh-cas-102747-84-2.html 2026-02-10T21:22:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-l-lysine-cas-13734-28-6.html 2026-02-10T21:22:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/cbz-ala-pro-oh-cas-21027-01-0.html 2026-02-10T21:22:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/tetradecanedioic-acid-cas-821-38-5.html 2026-02-10T21:22:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-tyr-tbu-oh-cas-18822-59-8.html 2026-02-10T21:22:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-arg-no2-oh-cas-2188-18-3.html 2026-02-10T21:22:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/boc-glycine-cas-4530-20-5.html 2026-02-10T21:21:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/fmoc-l-pro-oh-cas-71989-31-6.html 2026-02-10T21:21:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/octa-otbu-glu-otbu-cas-1188328-39-3.html 2026-02-10T21:22:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/apis-and-intermediates/h-ser-tbu-oh-cas-18822-58-7.html 2020-01-07T04:47:43+08:00 weekly 0.9 https://fi.hsp-pharma.com/newslist-386802-1 2020-01-07T05:19:37+08:00 weekly 0.9 https://fi.hsp-pharma.com/newslist-386813-1 2019-11-27T05:43:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/prospects-for-the-development-of-chinese-apis-29489773.html 2019-11-27T05:42:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fluorinated-pyridine-intermediates-become-hot-29489774.html 2019-11-27T05:46:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/intermediate-type-29489775.html 2019-11-27T05:46:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/introduction-to-pharmaceutical-intermediates-29489776.html 2019-11-27T05:43:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/development-status-of-raw-materials-29489779.html 2019-11-27T05:46:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/problems-in-the-development-of-china-s-apis-29489807.html 2019-11-27T05:46:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/domestic-and-international-environment-for-the-29489809.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/increased-demand-for-pharmaceutical-intermedia-29489895.html 2019-11-27T05:46:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-most-basic-conditions-for-pharmaceutical-i-29489921.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/large-gap-in-pharmaceutical-intermediates-29489922.html 2019-11-27T05:43:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/introduction-of-api-29490009.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/domestic-production-of-api-29490010.html 2019-11-27T05:46:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/drug-supplies-concept-29490011.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/introduction-to-intermediates-29490012.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pharmaceutical-preparation-29490089.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/technical-requirements-for-pharmaceutical-inte-29490090.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pharmaceutical-intermediate-characteristics-29490165.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/larger-aminophenol-gap-29535657.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/china-s-raw-material-development-status-29591174.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-track-of-pharmaceutical-intermediates-came-29689427.html 2020-01-16T00:01:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-research-team-assembles-living-robot-wi-31187731.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-efficacy-and-prospect-of-ibrutinib-31187732.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/trimethylhydroquinone-has-a-promising-market-31187733.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-generation-antiepileptic-drug-of-fycom-31187763.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/incyte-and-morphosys-reach-cooperation-to-deve-31187844.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-drugs-for-schizophrenia-intra-cellular-th-31187847.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nmpa-publishes-guidelines-for-the-research-on-31187850.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/development-history-of-gv971-31187883.html 2020-01-16T12:59:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/progress-in-the-analysis-and-evolution-of-nad-31213469.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nampt-linking-nad-biology-metabolism-and-canc-31213792.html 2020-01-16T13:04:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/immunity-chinese-scientists-have-revealed-tha-31213794.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/researchers-find-brain-receptors-that-change-m-31213860.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/china-s-original-new-drug-for-treating-alzheim-31213952.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/scientists-have-pried-the-bone-of-cancer-treat-31240115.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/olaparib-combination-therapy-receives-priority-31240146.html 2020-01-17T22:16:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-research-promises-to-stop-some-sand-viruse-31269890.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nature-amazing-the-thin-metal-membrane-deliv-31270117.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nad-anti-aging-31270176.html 2020-01-17T22:23:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/china-s-original-anti-cancer-drug-zanubrutinib-31270178.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cancer-immunotherapy-upgrade-33448185.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/breakthrough-using-live-virus-to-identify-33448189.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/parp-inhibitor-olaparib-prostate-cancer-market-33448249.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-clenbuterol-ointment-2-for-sup-33448253.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/acs-cent-sci-study-summarizes-potential-covid-33448271.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/chemrxiv-breakthrough-researchers-screened-ne-33448272.html 2020-05-01T18:22:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cheap-drug-may-alleviate-treatment-resistance-33485063.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-successfully-completes-the-acquisition-o-33485081.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/front-oncol-new-discovery-lactic-acid-may-pr-33485082.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/three-nature-on-the-same-day-provides-new-per-33485083.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-evidence-obesity-is-linked-to-covid-19-s-33485085.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-drug-for-type-2-diabetes-dorzagliatin-33527251.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nejm-new-coronavirus-2019-ncov-covid-19-pos-33527330.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cgh-gastroenterologists-and-patients-with-chr-33527344.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/key-clinical-trials-to-test-chloroquine-and-az-33527365.html 2020-05-02T23:15:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ajr-chinese-scientists-have-found-that-chest-33527367.html 2020-05-02T23:16:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/treatment-of-rare-lung-diseases-boehringer-ing-33527369.html 2020-05-02T23:19:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inter-j-cancer-cocoon-trigger-melanoma-suici-33527425.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-new-indication-for-somaglutide-to-33527426.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-delays-review-of-intercept-s-potential-nas-33527427.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-s-potent-egfr-small-molecule-tyrosine-k-33527428.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-s-heavyweight-cd38-targeted-33527429.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-steroid-refractory-acute-graft-versu-33527488.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/notice-on-spring-festival-holiday-in-33527489.html 2020-05-02T23:18:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-and-prothera-cooperate-to-develop-a-new-33527490.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nerlynx-neratinib-is-listed-in-singapore-re-33527491.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lynparza-the-first-parpi-to-treat-homologous-33527493.html 2020-05-02T23:19:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-national-drug-administration-nmpa-accept-33527496.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lymphoma-new-drug-tg-therapeutics-next-genera-33527555.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-advisory-committee-fails-to-agree-on-appro-33527558.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-announces-the-official-launch-of-33527559.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nature-medicine-paper-points-out-a-new-coronav-33527561.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/comprehensive-analysis-where-does-the-new-cor-33564364.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/break-the-textbook-the-nature-sub-discovery-f-33564398.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-s-brain-permeable-btk-inhibitor-sar-33564399.html 2020-05-04T00:19:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nejm-the-new-coronavirus-sars-cov-2-maintains-33564400.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/can-chloroquine-and-hydroxychloroquine-treat-c-33564422.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-squibb-nektar-star-immunostimu-33564443.html 2020-05-04T00:20:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-brief-history-of-coronavirus-take-you-to-un-33564445.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/chinese-scientists-found-that-nearly-half-of-p-33564485.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/yovant-oral-relugolix-a-gnrh-receptor-antagon-33564543.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/by-inhibiting-the-body-s-own-proteins-it-is-e-33591701.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-new-class-of-antihyperglycemic-drugs-imeglim-33591739.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/dostarlimab-shows-strong-efficacy-in-the-treat-33626019.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-issues-15-orphan-drugs-a-week-33626037.html 2020-05-08T09:07:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-pcsk9-inhibitor-polyida-launched-in-ch-33675875.html 2020-05-08T09:10:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/genome-company-s-first-anti-cancer-microbiot-33675920.html 2020-05-08T09:06:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/boehringer-ingelheim-ofev-is-approved-by-the-e-33675925.html 2020-05-08T09:04:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/breakthrough-pruritus-therapy-reaches-phase-33675926.html 2020-05-08T09:06:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/transcon-human-growth-hormone-obtains-u-s-and-33675978.html 2020-05-08T09:10:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/breakthrough-pruritus-therapy-reaches-phase-33675979.html 2020-05-08T09:10:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/visen-pharma-announces-transcontm-human-growth-33675980.html 2020-05-08T09:13:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-mayzent-treatment-continues-to-slow-d-33676038.html 2020-05-08T09:09:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/low-dose-doxorubicin-may-overcome-leukemia-res-33676071.html 2020-05-08T09:10:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-kinase-inhibitor-koselugo-selumet-33676073.html 2020-05-08T09:13:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/beigene-s-first-line-treatment-of-advanced-ind-33676105.html 2020-05-08T09:15:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-multiple-sclerosis-new-drug-ocrevus-prog-33676106.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-phase-iii-project-of-oral-non-azole-33676107.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zaiding-pharmaceutical-zele-nilapali-supple-33676124.html 2020-05-08T09:11:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cell-reveal-how-tissue-protects-dna-from-dama-33676125.html 2020-05-08T09:15:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/surufatinib-was-awarded-2-fast-track-qualifica-33676126.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/preventive-immunotherapy-monoclonal-antibody-t-33676127.html 2020-05-08T09:23:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/use-chloroquine-to-treat-new-coronary-pneumoni-33676177.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/dapoxetine-hydrochloride-tablets-and-cinacalce-33676178.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/heavy-weight-immunotherapy-drug-tecentriq-laun-33676182.html 2020-05-08T09:20:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/remdesivir-early-medication-can-prevent-the-d-33676223.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/j-comput-biol-a-new-method-to-predict-the-tar-33676226.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-key-clinical-study-of-the-first-non-dopami-33676227.html 2020-05-08T09:18:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jama-cardiol-be-alert-unstable-blood-pressur-33676233.html 2020-05-08T09:23:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-reached-an-agreement-with-the-us-fda-33676273.html 2020-05-08T09:23:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/plos-pathog-real-hammer-antiviral-drug-baloxa-33676274.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-eucrisa-ointment-has-been-approved-by-t-33676277.html 2020-05-08T09:23:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/otsuka-and-esperion-sign-an-exclusive-agreemen-33676279.html 2020-05-08T09:20:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/yangzijiang-bomadiamine-capsule-application-fo-33676280.html 2020-05-08T09:20:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jbc-new-research-shows-that-redoxivir-can-eff-33676283.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/japanese-team-finds-natural-plants-that-can-ef-33676332.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nejm-new-drug-can-be-used-to-treat-schizophre-33676333.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-generation-pi3k-inhibitor-new-cd20-33676334.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-zolgensma-intrathecal-injection-shows-33676335.html 2020-05-08T09:20:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alcohol-is-harmful-so-how-does-alcohol-weaken-33676336.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sci-rep-potential-therapy-can-be-used-to-trea-33676386.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-helsen-akynzeo-intravenous-preparation-has-33676430.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cinda-bio-partners-incyte-s-powerful-fgfr-kina-33676432.html 2020-05-08T17:44:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/heplatin-s-batoclimab-phase-1b-2a-clinical-s-33694388.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/terlipressin-is-under-review-in-the-united-sta-33694591.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/trodelvy-the-first-trop-2-targeted-antibody-d-33694927.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-bms-immune-combination-opdivo-yervoy-fir-33696708.html 2020-05-08T18:17:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ebola-heavy-news-the-regenerative-third-antib-33696792.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-total-of-20-domestic-first-class-new-drugs-h-33697454.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-antidiabetic-drug-farxiga-was-ap-33697571.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alnylam-s-another-rnai-therapy-gets-fda-fast-t-33697607.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-imbruvica-ibrutini-was-a-33729740.html 2020-05-09T14:16:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bms-exelixis-combination-therapy-cabometyx-33730296.html 2020-05-09T14:57:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-non-surgical-treatment-for-low-grade-33731569.html 2020-05-10T05:10:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/breast-cancer-diagnosis-and-treatment-guidelin-33754988.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/transcon-pth-a-long-acting-alternative-therap-33777264.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/vitrakvi-is-approved-in-the-uk-for-the-treatme-33835547.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-abbvie-venclexta-combination-therapy-p-33837369.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-targeted-anticancer-drug-cabometyx-cab-34696396.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pi3k-inhibitor-me-401-is-qualified-by-the-us-34696398.html 2020-06-09T01:08:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ocaliva-oca-obeticholic-acid-was-postponed-34696399.html 2020-06-09T01:08:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-completes-all-acquisitions-of-aierjian-34696400.html 2020-06-09T01:08:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-s-remdesvir-veklury-received-the-wor-34696401.html 2020-06-09T01:08:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-announces-strong-data-for-evobrutinib-mu-34696402.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-antibacterial-drug-mgb-bp-3-has-a-cure-34696403.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/dapoxetine-hydrochloride-tablets-and-cinacalce-34696404.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-farinyl-transferase-inhibitor-zokinv-34696405.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-s-oral-jak1-inhibitor-rinvoq-submitted-34696406.html 2020-06-09T01:08:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-clinical-trial-of-anti-tumor-drug-34696408.html 2020-06-09T01:08:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-s-jak1-inhibitor-filgotinib-is-successf-34696409.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nash-new-drug-reaches-phase-2-clinical-end-poi-34696551.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-regenerative-dupixent-s-phase-iii-clini-34696552.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-kynmobi-apomorphine-sublingual-f-34696553.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-granted-moderna-s-vaccine-product-m-34696554.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-and-iavi-have-jointly-developed-the-covi-34696558.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jelmyto-the-first-low-grade-upper-urothelial-34715614.html 2020-06-09T09:48:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cytiva-the-global-leader-in-life-sciences-is-34715615.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-tepmetko-approved-the-world-s-first-ora-34715617.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/aveo-targeted-anticancer-drug-tivozanib-is-app-34715618.html 2020-06-09T09:48:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-gnrh-receptor-antagonist-prostate-cancer-34715619.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-takes-back-the-global-rights-of-il-34715621.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fennec-s-pedmark-sodium-thiosulfate-received-34715799.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-adc-jointly-developed-by-astrazeneca-and-d-34715800.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-cornerstone-pharmaceutical-partner-bluepri-34715801.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/treatment-of-specific-lung-cancer-eli-lilly-s-34715802.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/olapali-combination-therapy-approved-by-fda-34715805.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-targeted-anti-cancer-drug-vitrakvi-has-34716057.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/treatment-of-gastric-cancer-cd39-inhibitor-k-34727536.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-ocrevus-new-infusion-solution-approved-b-34727537.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/amgen-s-new-myocardial-myosin-activator-omecam-34727651.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/small-molecule-drug-onc201-brings-hope-to-pati-34728469.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-world-s-first-deuterated-drug-austedo-was-34733734.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/kaposi-s-sarcoma-ks-heavyweight-the-only-or-34733786.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/epclusa-approved-for-children-with-hepatitis-c-34733804.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/qinlock-the-first-four-line-drug-kinase-inhib-34736765.html 2020-06-09T21:48:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/epidiolex-received-priority-review-by-the-us-f-34736766.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-second-phase-iii-trial-of-sanclifi-cd38-an-34736842.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-tecentriq-avastin-first-line-treatment-s-34738414.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-grants-astrazeneca-enhertu-a-breakt-34738415.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/china-lung-cancer-rare-mutual-collaboration-gr-34738473.html 2020-06-10T03:55:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-first-new-kaposi-sarcoma-drug-in-34740968.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-cd38-antibody-sarclisa-combination-ther-35503733.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-ocrevus-new-infusion-solution-approved-b-35503734.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-nuclear-export-inhibitor-xpovio-was-35503735.html 2020-06-29T18:39:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-first-tivicay-dispersible-tablet-35503736.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-cd38-antibody-sarclisa-was-approved-by-35503737.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/hualing-pharmaceutical-completes-seed-study-of-35503738.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-new-generation-of-oral-jak1-inhibitor-35503739.html 2020-06-29T19:10:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/luye-pharmaceutical-s-innovative-drug-zepzelca-35505362.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-oriahnn-approved-for-menstrual-bleeding-35505363.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-gives-green-light-to-astrazeneca-ticagrelo-35505364.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/treatment-of-atopic-dermatitis-pfizer-jak1-inh-35505366.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-antibody-drug-conjugate-adc-for-rh-35505510.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-oral-jak1-inhibitor-releases-complete-p-35505533.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-double-acting-orexin-receptor-antagonist-35505534.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-recarbrio-is-approved-by-the-us-fda-for-35505535.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-opdivo-is-approved-by-the-us-fda-35505538.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-lyumjev-is-approved-by-the-us-fda-35505562.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-releases-new-data-on-risdiplam-treatment-35505675.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-gnrh-receptor-antagonist-prostate-cancer-35506125.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/otsuka-triple-reuptake-inhibitor-centanafadine-35506126.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/treatment-of-hospital-acquired-bacterial-pneum-35506190.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-gardasil-9-approved-by-the-fda-for-the-p-35506267.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-glp-1-agonist-semaglutide-weight-35506450.html 2020-06-29T19:35:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/wanchun-medicine-s-first-in-class-new-drug-rea-35506593.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-anti-inflammatory-drug-ilaris-is-appr-35506652.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-pfizer-mylotarg-treatment-1-mon-35506653.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/leaf-lead-anticancer-drug-leaf-140-preclinical-35506689.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/2-new-mechanism-drugs-nexletol-nexlizet-are-la-35506690.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-pompe-disease-second-generation-enzyme-35506692.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-pfizer-bavencio-maintenance-treatment-ph-35506723.html 2020-06-29T19:39:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-biosimilar-nyvepria-pefegrastim-is-35506821.html 2020-07-28T10:16:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-innovative-therapy-for-advanced-prostate-36490584.html 2020-07-28T10:16:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-s-fycompa-perampanel-new-fine-particle-36490589.html 2020-07-28T10:16:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-antidiabetic-drug-farxiga-dapag-36490590.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-has-accepted-the-supplementary-new-drug-ap-36490594.html 2020-07-28T10:21:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-rare-disease-drug-lumasiran-approved-in-th-36490940.html 2020-07-28T10:26:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvox-botox-botox-enters-the-us-for-review-36491111.html 2020-07-28T10:26:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-meiji-s-new-selective-mao-b-inhibitor-eq-36491112.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/albumin-bound-rapamycin-nab-sirolimus-is-app-36491137.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-gives-priority-to-reviewing-brilint-36491138.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-igg-antibody-cleaving-enzyme-idefirix-36491448.html 2020-07-28T10:31:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-triple-therapy-trikafta-phase-iii-was-succ-36491452.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-s-anti-insomnia-drug-lemborexant-submits-36491720.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-veklury-is-approved-the-first-european-36491724.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alexion-s-ultomiris-subcutaneous-preparation-p-36491726.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/boehringer-ingelheim-trajenta-linagliptin-h-36491728.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-granted-assembly-the-second-gener-36491967.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-five-new-drugs-received-japanese-app-36491970.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-peptide-drug-conjugate-melflufen-is-36492074.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/otsuka-samsca-tolvaptan-approved-in-japan-t-36492080.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-hedgehog-pathway-inhibitor-daurismo-app-36492084.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/for-the-treatment-of-lupus-nephritis-voclospo-36492256.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/qinlock-the-first-fourth-line-drug-announces-36492582.html 2020-07-28T10:53:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-s-btk-inhibitor-imbruvica-us-prescripti-36492664.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-granted-axs-05-dextromethorphan-bupropion-36492674.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-farxiga-has-obtained-the-us-fda-fa-36492835.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/qutenza-receives-fda-approval-for-the-treatmen-36492973.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jnj-invokana-approved-by-the-european-union-t-36494400.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-and-blueprint-signed-a-1-7-billion-agre-36494931.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/beigene-parp1-2-inhibitor-pamiparib-pamiparib-36495488.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-biktarvy-is-safe-and-effective-in-the-e-36495656.html 2020-08-10T16:53:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-p-selectin-inhibitor-adakveo-has-been-36929967.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-non-opioid-painkiller-zynrelef-bupiva-36929968.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-s-oral-jak1-inhibitor-jyseleca-filgoti-36930303.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-s-tecentriq-three-drug-regimen-was-appro-36930305.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/neupharma-class-1-new-drug-completes-first-pat-36930306.html 2020-08-10T17:05:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-btk-inhibitor-calquence-has-been-36930478.html 2020-08-10T17:06:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/egfr-targeted-drug-cures-early-stage-lung-canc-36930480.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/biomarin-s-c-type-natriuretic-peptide-analogue-36930680.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/avapritinib-will-be-approved-in-the-eu-in-sept-36930681.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-imbruvica-ibrutinib-combin-36930682.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/beigene-s-parp1-2-inhibitor-pamiparib-new-drug-36930684.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-farxiga-dapagliflozin-phase-ii-36932458.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/qilu-pharmaceutical-and-sesen-bio-reached-a-37134637.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-s-spravato-nasal-spray-was-a-37135509.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-and-merck-s-bavencio-inlyta-combination-37136495.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-eisai-submitted-a-new-indication-applica-37136496.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-s-first-nae-inhibitor-pevonedistat-has-37136572.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-china-2020-our-booth-num-37410060.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/progress-in-the-construction-of-chiral-1-4-dia-37410505.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-lampit-nifurolimus-easily-dispersible-37416387.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-granted-the-pan-pi3k-inhibitor-pa-37418786.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-granted-the-breakthrough-drug-desig-37418867.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/canbridge-nerlynx-neratinib-is-approved-for-37437071.html 2020-08-25T21:25:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-and-gilead-signed-a-multi-year-agreemen-37443510.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/dovato-a-complete-two-drug-regimen-of-glaxosm-37446885.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-new-class-of-hypoglycemic-drug-imeglimin-sub-37447119.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-s-ret-inhibitor-pratinib-s-marketing-ap-37782523.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-igg-antibody-cutting-enzyme-idefirix-h-37782526.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/beyondspring-first-in-class-new-drug-plenabuli-37782527.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-keytruda-obtains-two-latest-approvals-37782530.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-granted-fast-track-qualification-37782534.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/treatment-of-specific-non-small-cell-lung-canc-37783673.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-s-oral-jak-inhibitor-rinvoq-upadacitin-37783676.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/trilaciclib-s-treatment-of-small-cell-lung-can-37790797.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/hepanova-s-first-in-class-nash-new-drug-is-cli-37790798.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-forxiga-significantly-reduces-the-37790803.html 2020-09-04T20:36:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/for-small-cell-lung-cancer-luye-pharma-s-intr-37793831.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/erleada-was-approved-in-china-for-a-new-indica-37793839.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/biomarin-s-c-type-natriuretic-peptide-analogue-37794138.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-met-inhibitor-tepotinib-has-been-given-37794643.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-retrospective-study-of-giotag-afatinib-os-38074343.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-onureg-the-first-aml-cont-38074344.html 2020-09-15T19:40:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-zeposia-has-long-term-efficacy-a-38088929.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/disk-sogroya-is-approved-by-the-us-fda-the-fi-38089199.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/vimpat-phase-iii-clinical-success-in-the-treat-38089200.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-powerful-met-inhibitor-tabrecta-has-38109147.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/amgen-s-pcsk9-inhibitor-repatha-pediatric-phas-38157938.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-dpp1-inhibitor-brensocatib-significa-38485738.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/boehringer-ingelheim-terminates-the-aoc3-inhib-38485754.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-p2x3-receptor-antagonist-gefapixant-ha-38485798.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ryplazim-plasminogen-once-again-applied-for-38485801.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-galapagos-selective-atx-inhibitor-zirit-38485809.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/mallinckrodt-kidney-failure-drug-rejected-by-f-38485810.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lynparza-olaparib-first-line-maintenance-tre-38485814.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-successful-phase-iii-of-the-potent-ileal-b-38496765.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-imbruvica-ibrutinib-combin-38496766.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-eu-chmp-recommends-the-approval-of-zejula-38496958.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/chi-med-surufatinib-s-second-nda-accepted-for-38497064.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bms-exelixis-combination-therapy-opdivo-cabome-38497065.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-verzenio-the-first-cdk4-6-inhibitor-38497068.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-combination-of-merck-eisai-keytruda-lenvim-38497070.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-abemaciclib-significantly-reduces-hr-38497071.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/antengene-atg-010-selinexor-for-the-treatmen-38497072.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-acquires-next-generation-oral-pcsk-38497073.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-tafinlar-mekinist-targeted-therapy-fo-38497074.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/construction-of-dual-kras-inhibitor-combinatio-38497084.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-olumiant-s-new-indication-has-been-r-38519374.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/3-years-after-one-time-administration-of-nbib-38544484.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-acquires-immunomedics-a-developer-of-n-38569090.html 2020-10-01T13:52:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/tagrisso-osimertinib-adjuvant-treatment-of-e-38599657.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ayvakit-shows-strong-efficacy-in-the-treatment-38599786.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/spectrum-s-next-generation-tki-zai-lab-submits-38599847.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-adempas-riociguat-phase-iv-study-is-su-38599854.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/concord-kylin-crysvita-has-been-approved-by-th-38801925.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/three-year-phase-iii-clinical-data-of-glaxosmi-38802184.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-medicine-for-acute-treatment-of-migraine-38810147.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-granted-farxiga-dapagliflozin-bre-38810530.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-once-a-week-long-acting-drug-somatrogon-38810533.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-granted-imgn632-a-breakthrough-drug-38811025.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-european-union-approves-the-new-non-opioid-38811720.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-world-s-first-siderophore-cephalosporin-fe-38821769.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-palynziq-label-update-the-38822183.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/for-juvenile-idiopathic-arthritis-pfizer-xelj-38825803.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/kynmobi-apomorphine-hcl-launched-in-the-us-38843108.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-dulaglutide-is-approved-for-patie-38871226.html 2020-10-26T12:03:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/96-week-phase-iii-clinical-data-of-glaxosmithk-39155402.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-unique-cationic-hydroxybutyrate-therapy-xy-39155405.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-2dr-first-line-treatment-of-hiv-phase-39155725.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/innovative-introduction-boao-lecheng-landed-c-39162401.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/savolitinib-has-many-surprises-and-has-great-p-39162673.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alks3831-olanzapine-samidorphan-is-about-to-39162980.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-phase-3-clinical-study-of-lumasiran-in-the-39166746.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gsk-ileal-bile-acid-transporter-inhibitor-line-40064970.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-first-drug-finerenone-applied-for-li-40064971.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/nurtec-odt-is-under-review-in-the-united-state-40065117.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-first-drug-finerenone-phase-3-clinical-40065123.html 2020-11-25T10:53:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-oral-selective-complement-c5a-recept-40065129.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-deuterated-jak1-2-inhibitor-ctp-543-ha-40065133.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-phase-3-clinical-trial-of-xpovio-th-40065134.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-olumiant-baricitinib-has-long-term-40065138.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-xarelto-rivaroxaban-is-about-to-be-app-40065145.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-new-generation-of-oral-jak1-inhibitor-40065292.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/long-acting-injection-of-cabotegravir-once-eve-40065298.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-dupixent-for-the-first-time-showed-sign-40065381.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-squibb-takes-oral-tyk2-inhibitor-40065383.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/biomarin-s-c-type-natriuretic-peptide-analogue-40065386.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alnylam-s-third-rnai-therapy-lumasiran-is-abou-40067071.html 2020-11-25T11:31:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-olumiant-s-baricitinib-new-indicati-40067072.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-acquired-disarm-therapeutics-for-us-40067109.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-s-oral-jak1-inhibitor-jyseleca-has-appl-40067112.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/menarini-elzonris-is-about-to-be-approved-in-t-40067114.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-evrysdi-applied-for-listing-in-japan-and-40067115.html 2020-11-25T11:59:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-xtandi-is-approved-to-treat-non-meta-40067821.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/glaxosmithkline-zejula-niraparib-approved-by-40068033.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-tecentriq-immune-combination-therapy-pro-40068783.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fintepla-is-recommended-and-approved-by-the-eu-40068907.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/daxibotulinumtoxina-phase-3-clinical-trial-was-40069591.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-squibb-took-oral-tyk2-inhibitor-40076420.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-amgen-tslp-targeted-monoclonal-ant-40085061.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-btk-inhibitor-calquence-acalabr-40085064.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/russia-approves-the-second-covid-19-vaccine-e-40085553.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pradaxa-dabigatran-etexilate-the-first-drug-40098858.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-and-the-gates-foundation-cooperate-to-c-40103354.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-phase-3-clinical-effect-of-merck-eisai-imm-40103547.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gsk-strong-growth-effect-intramuscular-injecti-40110403.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-hypoglycemic-drug-forxiga-dapag-40117486.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approved-vimpat-lacosamide-for-the-treat-41872035.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-evrenzo-roxadustat-approved-in-ja-41872039.html 2021-01-19T14:01:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gnrh-receptor-antagonist-yselty-linzagolix-e-41872041.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-stamp-inhibitor-asciminib-phase-iii-e-41872384.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alks3831-olanzapine-samidorphan-is-re-accept-41872385.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approved-orgovyx-a-gnrh-receptor-a-41872386.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/research-progress-on-biomimetic-total-synthesi-41872387.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eprenetapopt-azacitidine-is-better-than-azacit-41872389.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-eu-approves-sanofi-menquadfi-the-first-al-41872400.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/axsome-s-new-oral-multi-mechanism-drug-axs-41872401.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-and-mesoblast-signed-a-license-agreem-41872402.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zelgen-biopharmaceuticals-obeticholate-magnesi-41872404.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approved-takeda-s-third-generation-tk-41872405.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-s-oral-tyrosine-kinase-inhibitor-cabome-41872406.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-phase-3-nuclear-export-inhibitor-xpo-41872411.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/china-s-first-bcl-2-inhibitor-approved-veneto-41872434.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-jak-inhibitor-jakavi-successfully-tre-41872719.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-xospata-gilteritinib-first-line-tre-41872720.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-pioneering-sirna-cholesterol-lowerin-41872724.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-powerful-aak1-inhibitor-lx9211-enters-phas-41872728.html 2021-01-19T14:29:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-third-generation-alk-inhibitor-lorbr-41873930.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-lenvima-lenvatinib-post-marketing-stud-41874149.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/braf-v600e-mcrc-targeting-program-braftovi-tw-41874150.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-eu-approves-the-symkevi-and-kalydeco-joint-41874151.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-review-of-evrenzo-astrazeneca-evrenzo-ros-41874797.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-granted-amgen-sotorasib-breakthrough-dr-41874799.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-btk-inhibitor-calquence-acalabr-41874800.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/amgen-sotorasib-submitted-a-marketing-applicat-41874810.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-roche-abbvie-venclexta-ritual-solution-ha-41875092.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-s-glp-1-agonist-semaglutide-appli-41875093.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-btk-inhibitor-calquence-acalabr-41875436.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/axs-05-dextromethorphan-bupropion-modified-re-41875671.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-s-oral-jak1-inhibitor-jyseleca-is-launc-41876649.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-new-drug-to-treat-obesity-caused-by-41876843.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-s-cd79b-targeted-drug-polivy-bendamustin-41877682.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/3-adrenergic-receptor-agonist-gemtesa-vibegr-41877685.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-third-generation-alk-inhibitor-lorbr-41878385.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-and-powerful-mc4r-agonist-imcivree-41878397.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-world-s-first-long-acting-injection-regime-41879173.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fintepla-fenfluramine-is-approved-by-the-eur-41880675.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-fycompa-perampanel-has-been-approved-b-41882360.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-s-oral-jak1-inhibitor-jyseleca-filgoti-41882846.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-phase-3-nuclear-export-inhibitor-xpo-41882848.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approved-vimpat-lacosamide-for-the-41882849.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/verrica-s-vp-102-cantharidin-0-7-topical-so-41883755.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cabometyx-cabozantinib-phase-3-clinical-tria-41884018.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-novo-nordisk-glp-1-recepto-41884396.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-forxiga-dapagliflozin-approved-i-41884460.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-fda-granted-the-new-liposomal-anthracyclin-41889114.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/hutchison-medical-s-surufatinib-was-approved-41889307.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-btk-inhibitor-imbruvica-ibrutinib-us-41890410.html 2021-01-19T21:06:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-loxo-305-has-shown-strong-efficacy-i-41890608.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/best-in-class-gnrh-receptor-antagonist-yselty-41894671.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-verzenio-the-first-cdk4-6-inhibitor-41896275.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-adjuvant-postoperative-therapy-eg-41900929.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-johnson-johnson-darzalex-faspro-42487661.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/progress-in-the-development-of-new-and-efficie-42487662.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sgl1-2-inhibitor-zynquista-sotagliflozin-rec-42487663.html 2021-02-04T17:42:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gsk-single-dose-kozenis-tafenoquine-effecti-42487664.html 2021-02-04T17:42:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cxcl-8-inhibitor-ladrixin-enters-phase-3-clini-42487665.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/visen-pharmaceuticals-transcon-c-type-natriure-42487666.html 2021-02-04T17:42:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-pharmaceuticals-agios-pioneered-idh1-in-42487667.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-pf-06939926-phase-iii-clinical-study-42487668.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-bayer-nubeqa-arolutamide-p-42487669.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-world-s-first-multiple-myeloma-drug-seline-42487670.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-s-super-flu-drug-xofluza-was-approved-by-42487672.html 2021-02-04T17:42:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-and-merus-reach-1-6-billion-coopera-42487674.html 2021-02-04T17:42:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/menarini-elzonris-approved-in-the-eu-treatmen-42487675.html 2021-02-04T17:42:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-s-oral-jak1-inhibitor-rinvoq-upadaciti-42487676.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-esbriet-pirfenidone-received-priority-42487884.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approved-the-inhibitor-lupkynis-for-42508282.html 2021-02-05T05:39:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/opdivo-cabometyx-program-was-approved-by-the-u-42508296.html 2021-02-05T13:06:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/acalabrutinib-vs-ibrutinib-in-the-treatment-o-42521858.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-calquence-has-higher-clinical-safe-42521859.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-s-faricimab-is-successful-in-the-treatme-43383734.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/vertex-s-triple-therapy-trikafta-has-been-give-43383948.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oxbryta-voxelotor-enters-the-review-in-the-e-43383951.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/spring-festival-holiday-notice-43383954.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-xospata-gilteritinib-approved-trea-43384038.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/seattle-genetics-her2-targeted-tki-oral-drug-43384086.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-non-hormonal-therapy-fezolinetant-treatme-43384236.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-short-acting-cdk4-6-inhibito-43384237.html 2021-03-11T19:26:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-terminates-multiple-r-d-plans-such-as-p-43384238.html 2021-03-11T19:26:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-generation-of-oral-pi3k-ck1-dual-in-43384241.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/glaxosmithkline-rukobia-approved-by-eu-new-an-43384242.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-submitted-its-first-new-drug-listing-ap-43384393.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-dosage-form-of-ruxolitinib-has-been-re-43384394.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lynparza-olaparib-adjuvant-treatment-of-brca-43384397.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-maribavir-phase-3-clinical-success-43384470.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/biogen-waives-parkinson-s-disease-drug-cineman-43384519.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-gip-glp-1-dual-receptor-agonist-ti-43384520.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-erlead-apalutamide-zytig-43384745.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-odevixibat-has-been-given-priority-r-43386356.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-submits-a-long-acting-human-growth-horm-43386361.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/antengene-atg-010-new-drug-marketing-applicati-43386364.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-s-pralsetinib-in-the-treatment-of-chine-43386489.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-tepmetko-the-world-s-firs-43386493.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-european-union-approves-sanofi-plavix-clo-43386526.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lamotrigine-is-approved-for-new-indications-b-43386545.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zeposia-ozanimod-for-the-treatment-of-ulcera-43386624.html 2021-03-11T20:00:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-world-s-first-chemotherapy-and-bone-marrow-43386638.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/in-february-2021-the-world-s-first-batch-of-43386753.html 2021-03-11T20:04:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zokinvy-is-listed-in-the-us-life-expectancy-i-43386863.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-s-next-generation-alk-inhibitor-alunbri-43386979.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-granted-novartis-stamp-inhibitor-as-43386993.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-national-food-and-drug-administration-of-c-43387046.html 2021-03-11T20:08:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-and-rigel-reached-a-us-960-million-a-43387056.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-tyk2-inhibitor-deucravacitinib-was-succes-43387064.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-gilteritinib-obtains-nmpa-conditional-43387075.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-first-drug-finerenone-applied-for-li-43387076.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/opdivo-cabometyx-combination-phase-3-clinical-43387085.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/smo-inhibitor-treatment-of-basal-cell-carcinom-43868993.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/galapagos-releases-mid-term-clinical-safety-da-43868994.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-incyte-olumiant-successfully-treats-43869227.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-s-cd38-targeting-antibody-sarclisa-s-se-43869301.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/use-artificial-intelligence-to-develop-innovat-43871311.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-third-generation-alk-inhibitor-lorbre-43871312.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-pi3k-inhibitors-apply-for-listing-in-c-43871314.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/successful-phase-ii-proof-of-concept-study-of-43873379.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-inhibitor-lenacapavir-maintained-high-v-43874572.html 2021-03-25T20:02:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-evrysdi-will-soon-be-approved-for-listin-43879387.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-s-oral-rinvoq-upadacitinib-new-indica-45725561.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/glaxosmithkline-s-long-acting-il-5-inhibitor-g-45725562.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pegcetacoplan-is-effective-in-treating-paroxys-45725563.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-and-novo-nordisk-join-forces-expand-cl-45725564.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-and-merck-jointly-develop-lenacapavir-i-45725565.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/everest-medicines-xerava-eravacycline-was-ac-45725568.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-ponvory-ponesimod-eu-is-ab-45725570.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-semaglutide-is-effective-18-2-w-45725573.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-breyanzi-liso-cel-approved-in-45725575.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-myrbetriq-mirabegron-is-approved-by-45726418.html 2021-05-17T13:39:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/2021-aacr-bayer-plans-to-announce-inhl-phase-45726420.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/simcere-and-kazia-signed-a-us-292-million-agre-45726421.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-broad-spectrum-targeted-anticancer-dru-45726422.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/blueprint-cstone-kit-inhibitor-ayvakit-avapri-45726423.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-lupkynis-regardless-of-the-biopsy-t-45726424.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zepzelca-lurbinectedin-was-included-in-the-c-45726425.html 2021-05-17T13:39:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/targeting-immunity-combination-keytruda-le-45726426.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-inhibitor-belumosudil-has-a-strong-effect-45726427.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-jak-inhibitor-baritinib-is-expecte-45726431.html 2021-05-17T13:39:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-acquisition-of-alexion-successfu-45726435.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-peptide-drug-conjugate-pepaxto-app-45726436.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/retevmo-is-very-effective-in-treating-various-45726437.html 2021-05-17T13:39:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/semaglutide-oral-50mg-enters-phase-3-clinic-45726439.html 2021-05-17T13:39:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/relugolix-compound-tablet-enters-phase-3-clini-45726440.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-merck-adempas-riociguat-has-a-strong-45727170.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-granted-the-inhibitor-futibatinib-45727175.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eu-approved-ontozry-cenobamate-adjuvant-tre-45727176.html 2021-05-17T13:50:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/darovasertib-in-the-treatment-of-metastatic-uv-45727179.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-and-celcuity-have-reached-a-partnership-45727180.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/3-adrenergic-receptor-agonist-gemtesa-vibegr-45727902.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/researchers-have-developed-a-new-generation-of-45741294.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-takhzyro-applied-for-listing-in-japan-45741295.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/johnson-johnson-ponvory-ponesimod-was-appr-45741296.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-peptide-drug-conjugate-pepaxto-was-i-45741297.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-verzenio-abemaciclib-combined-end-45741298.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-next-generation-vegf-tki-fotivda-is-launc-45741299.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-xtandi-enzalutamide-new-indication-45741300.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-abrocitinib-phase-3-clinical-effect-is-45741301.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-announces-evidence-of-the-efficacy-of-i-45741302.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/vertex-s-triple-therapy-kaftrio-and-ivacaftor-45741303.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-zegalogue-for-use-in-childre-45743078.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-ipsen-immune-targeting-combina-45743079.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-first-atr-inhibitor-berzosertib-topo-45743080.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/covalent-fgfr-inhibitor-futibatinib-in-the-tre-45743081.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oxbryta-voxelotor-treatment-for-72-weeks-sig-45743773.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-s-glp-1-receptor-agonist-saxenda-45756431.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-kimyrsa-oritavancin-tre-45756432.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-accepts-abbvie-atogepant-new-drug-applicat-45757334.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-incyte-olumiant-s-second-phase-3-tri-45757335.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-fabrazyme-the-only-enzyme-replacement-45770447.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/notification-of-address-change-46369531.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-abbvie-s-venclyxto-hypomethylation-agen-46369537.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-listing-application-of-hua-medicine-s-new-46369541.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-ozempic-semaglutide-injection-a-46369601.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-indication-of-astellas-xtandi-enzalut-46369735.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-jyseleca-applied-for-a-new-indication-i-46369741.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approved-the-inhibitor-empaveli-to-46369852.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/plasma-kallikrein-inhibitor-orladeyo-berotral-46374484.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eu-chmp-recommends-the-approval-of-onureg-aza-46374552.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-finerenone-phase-3-cardiovascular-outc-46374553.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-merck-eisai-keytruda-lenvima-program-submi-46374607.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/servier-tibsovo-has-been-given-priority-review-46376158.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-approves-farxiga-the-first-sglt2-inhib-46376184.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/daiichi-sankyo-tarlige-mirogabalin-applies-f-46376194.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/an-imported-anti-inflammatory-drug-otezla-is-u-46376263.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-maribavir-receives-priority-review-by-u-46376321.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-will-initiate-a-pivotal-phase-3a-46376626.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-the-new-non-opioid-dual-ac-46376740.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approved-truseltiq-infigratinib-46940121.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approved-tembexa-brincidofovir-t-46940122.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-approves-amgen-lumakras-the-world-s-fi-46940123.html 2021-06-23T11:56:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/olumiant-baricitinib-effectively-improves-pa-46940124.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gavreto-pralsetinib-has-shown-strong-and-lon-46940125.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lynparza-olaparib-adjuvant-treatment-of-brca-46940126.html 2021-06-23T11:56:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-verzenio-abemaciclib-endocrine-t-46940127.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-long-term-data-of-vitrakvi-larotrectinib-46940129.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novo-nordisk-submitted-ozempic-semaglutide-h-46940579.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bylvay-odevixibat-is-about-to-be-approved-in-46940580.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pi3k-inhibitor-zandelisib-in-the-treatment-of-46940581.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-opdivo-yervoy-program-is-recomme-46940582.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ipsen-palovarotene-has-entered-priority-review-46940583.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approved-ryplazim-plasminogen-th-46940584.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-gnrh-receptor-antagonist-relugolix-compou-46940586.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/erleada-apalutamide-long-term-treatment-pro-46940587.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/empaveli-has-a-strong-first-line-treatment-for-46940946.html 2021-06-24T07:11:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-indication-of-boehringer-lilly-jardian-46984513.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/amgen-lumakras-has-strong-efficacy-in-treating-46985438.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-oral-inhibitor-iptacopan-significant-46985439.html 2021-06-24T07:39:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-accepts-a-new-generation-of-pi3k-46985440.html 2021-06-24T07:39:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/wegovy-semaglutide-18-weight-loss-after-46985442.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-imbruvica-venclexta-fixed-course-of-fir-46985448.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-inhibitor-iptacopan-is-effective-in-treati-49916263.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-inhibitor-tazverik-is-approved-for-marke-49916264.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/efgartigimod-significantly-improved-strength-a-49916265.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/premier-research-acquires-camargo-a-u-s-phar-49916266.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/kras-inhibitor-adagrasib-has-been-certified-as-49916267.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-verquvo-vericiguat-is-approved-in-japa-49916268.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/parp-inhibitor-lynparza-olaparib-approved-t-49916297.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-update-of-aduhelm-label-for-49916693.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lupkynis-applied-for-listing-in-the-eu-it-can-49916694.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/beigene-kyprolis-carfilzomib-for-injection-a-49916695.html 2021-09-26T12:46:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-narrows-indications-for-biogen-s-alzheimer-49916696.html 2021-09-26T12:46:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-darzalex-faspro-combined-49916697.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-granted-alk-001-c20-d3-vitamin-a-49916698.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jakavi-jakafi-is-effective-in-treating-steroid-49916699.html 2021-09-26T12:46:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/universal-targeted-drugs-can-reduce-the-risk-o-49916700.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/phase-1b-study-of-oral-tyk2-inhibitor-glpg-49916701.html 2021-09-26T12:46:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/wakix-pitolisant-submitted-a-marketing-appl-49916702.html 2021-09-26T12:46:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-granted-takeda-s-oral-orexin-rece-49916703.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/science-sub-journal-defeat-drug-resistance-an-49916704.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-refuses-to-approve-nhe3-inhibitor-ten-49916705.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jakavi-jakafi-is-effective-in-treating-steroid-49916706.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eu-approved-imcivree-setmelanotide-rebuild-49916707.html 2021-09-26T12:46:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/concord-kirin-nourianz-was-rejected-by-the-eu-49916708.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-2-jak-inhibitors-abrocitinib-tofaci-49916709.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-uk-approves-the-third-indication-of-epidyo-49916710.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-granted-vivet-pfizer-vtx-801-fast-tra-49916711.html 2021-09-26T12:46:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cabenuva-can-be-successfully-implemented-in-a-49916712.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-first-antagonist-elinzanetant-enters-p-49916713.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-and-daiichi-sankyo-reached-a-commerc-49916714.html 2021-09-26T12:46:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-s-next-generation-anti-epileptic-drug-fy-49916715.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jyseleca-quickly-improve-symptoms-and-lasting-49916716.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-merck-s-innovative-tumor-drug-49916717.html 2021-09-26T12:47:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/igf-1r-targeting-monoclonal-antibody-tepezza-e-49916718.html 2021-09-26T12:46:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approved-johnson-johnson-invega-hafyera-49916719.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-first-drug-kerendia-finerenone-has-r-49916720.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-grants-jardiance-empagliflozin-brea-49916721.html 2021-09-26T12:46:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-u-s-fda-approves-the-innovative-periphera-49916722.html 2021-09-26T12:47:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-new-generation-of-oral-jak1-inhibitor-49916723.html 2021-09-26T12:47:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-oral-antiviral-drug-molnupiravir-enter-49916724.html 2021-09-26T12:46:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-tofacitinib-phase-3-clinical-phase-re-49916725.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-pharmaceuticals-obtains-fda-approval-fo-49917129.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-listing-application-of-pemigatinib-was-acc-49917132.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-granted-breakthrough-therapy-designatio-49917133.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-revoked-the-breakthrough-therapy-de-49917134.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/plasma-kallikrein-inhibitor-orladeyo-berotral-49917135.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-1-billion-acquisition-of-protomer-49917136.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/kimyrsa-oritavancin-launched-treatment-of-a-49917137.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fetcroja-cefiderocol-strong-activity-agains-49917138.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eprenetapopt-azacitidine-49917139.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fexinidazole-is-approved-by-the-us-fda-only-n-49917140.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eu-approves-powerful-ileal-bile-acid-transport-49917141.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-refuses-to-approve-nhe3-inhibitor-ten-49917142.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-evrysdi-risdiplam-significantly-improv-49917143.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-presbyopia-eye-drops-agn-190584-pil-49917144.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-approves-new-acne-drug-twyneo-tretinoi-49917145.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-sulopenem-for-the-treatment-of-simple-uri-49917146.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-lenacapavir-gs-6207-enters-the-review-49917147.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/oral-sulopenem-for-the-treatment-of-simple-uri-49917148.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-lenacapavir-gs-6207-enters-the-review-49917149.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-clinical-study-of-ibi362-in-chinese-overwe-49917150.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fibrogen-astellas-evrenzo-rosarestat-approve-49917151.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/otsuka-rexulti-brexpiprazole-orally-disinteg-49917152.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/takeda-s-new-drug-brigatinib-tablets-introduce-49917153.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-bms-immunomodulator-orencia-abatacept-ha-49917154.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-s-forxiga-dapagliflozin-is-appro-49917155.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-eliapixant-phase-2-clinical-effect-rea-49917156.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-grants-jardiance-empagliflozin-brea-49917157.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-new-generation-of-oral-jak1-inhibitor-49917158.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astellas-and-minovia-reached-a-strategic-coope-49917159.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-new-class-of-hypoglycemic-drug-twymeeg-imeg-49923105.html 2021-09-26T17:27:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/onureg-5-azacytidine-tablets-approved-by-the-49923106.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-immunological-drug-spesolimab-obtained-cde-49923107.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-european-union-approves-xeljanz-tofacitin-49923108.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-oral-pkr-allosteric-activator-mitapi-49923111.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sanofi-aubagio-teriflunomide-approved-by-the-49923119.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/sofatinib-was-approved-for-a-new-indication-t-49923360.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zynlonta-is-effective-in-treating-malignant-ly-49923361.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/venclyxto-gazyvaro-fixed-course-of-treatment-w-49923362.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eprenetapopt-azacitidine-is-effective-49923664.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fetcroja-cefiderocol-strong-activity-key-49923886.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-epclusa-has-been-approved-by-the-us-fda-49931018.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-dalvance-dalbavancin-si-49931289.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-s-new-generation-of-oral-jak1-inhibitor-49931296.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/low-throughput-screening-finds-anti-malarial-d-49931299.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/j-med-chem-research-and-development-of-new-49936708.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bayer-s-first-drug-kerendia-finerenone-was-49936710.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/alnylam-and-peptidream-have-reached-a-strategi-49936712.html 2021-09-27T05:16:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/beigene-brukinsa-zanubrutinib-was-approved-f-49936891.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-resubmitted-its-cholesterol-lowering-49936893.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-completes-the-acquisition-of-alexi-49939812.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-pioneering-sirna-cholesterol-lowerin-49939834.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-approves-merck-s-innovative-tumor-drug-49939836.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-pharmaceuticals-ivosidenib-has-released-49941347.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-european-union-approves-the-c-type-natriur-49941685.html 2021-09-27T09:47:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-evrysdi-risdiplam-significantly-sma-49942297.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fibrogen-astellas-evrenzo-rosarestat-approve-49949534.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jardiance-empagliflozin-the-first-drug-to-s-49949889.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zymeworks-her2-targeting-bispecific-antibody-s-51183158.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cabometyx-opdivo-has-a-good-effect-whether-51183159.html 2021-11-06T08:29:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-s-multispecific-antibody-clinical-trial-51183160.html 2021-11-06T08:29:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/astrazeneca-daiichi-sankyo-enhertu-head-to-hea-51183161.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cabometyx-opdivo-has-a-good-effect-whether-51183162.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/erleada-apalutamide-rapid-deep-and-lasting-51183163.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-peptide-drug-conjugate-pepaxto-in-th-51183164.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-tivdak-the-first-tissue-fac-51183165.html 2021-11-06T08:29:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-gavreto-pralsetinib-is-about-to-be-app-51183166.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-postpones-nefecon-targeted-release-b-51183170.html 2021-11-06T08:29:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-accepts-application-for-new-indication-51183171.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-galapagos-oral-jyseleca-will-soon-be-ap-51183172.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-first-peptide-drug-conjugate-pepaxto-in-th-51183173.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/verzenio-abemaciclib-the-first-cdk4-6-inhib-51183177.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-deucravacitinib-in-the-treatment-of-51183178.html 2021-11-06T08:29:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pfizer-biontech-announces-phase-3-clinical-dat-51183179.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/rinvoq-upadacitinib-phase-3-clinical-success-51183180.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/verzenio-abemaciclib-the-first-cdk4-6-inhib-51183181.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-gilead-low-dose-biktarvy-f-51183182.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-gilead-tecartus-a-single-51183183.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-gip-glp-1-dual-agonist-tirzepatide-51183184.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/a-new-generation-of-selective-nuclear-export-i-51183185.html 2021-11-06T08:29:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zeposia-is-about-to-be-approved-in-the-eu-the-51183186.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-us-fda-approves-abbvie-qulipta-the-first-51183188.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-and-neuexcell-have-reached-a-strategic-c-51183401.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/erleada-apalutamide-rapid-deep-and-lasting-51183402.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/giredestrant-neoadjuvant-treatment-of-er-her-51183403.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cs5001-ror1-adc-research-data-from-cstone-ph-51183404.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/selective-estrogen-receptor-degrading-agent-s-51183405.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lybalvi-olanzapine-samidorphan-is-launched-i-51183407.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-squibb-s-cardiac-myosin-alloster-51183410.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/xtandi-enzalutamide-phase-3-clinically-signi-51183411.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-immuno-oncology-therapy-ono-4685-enters-ph-51209645.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/researchers-announce-important-research-on-dor-51209646.html 2021-11-06T19:50:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/tyvaso-dpi-treprostinil-dry-powder-inhaler-51209650.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-accepts-application-for-new-indication-51210063.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/xtandi-enzalutamide-phase-3-clinically-signi-51210064.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/tyrvaya-varenicline-the-first-nasal-spray-t-51210065.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-gavreto-pralsetinib-is-about-to-be-app-51210067.html 2021-11-07T01:56:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/twymeeg-imeglimin-goes-on-sale-in-japan-tar-51221908.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/cstone-pharmaceuticals-esmo-announces-ivosiden-51230499.html 2021-11-26T20:26:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/gilead-mersk-s-lenacapavir-islatravir-once-a-w-52005191.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approved-abbvie-vuity-pilocarpine-52005193.html 2021-11-26T20:26:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-ridgeback-antiviral-drug-lagevrio-molnu-52005204.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/zuranolone-treatment-of-major-depression-mdd-52005420.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/roche-and-bicycle-expand-cooperation-develop-52005421.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/tatacept-iga-nephropathy-phase-ii-data-present-52005422.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/wegovy-semaglutide-is-about-to-be-approved-i-52020003.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/tebipenem-hbr-filed-for-listing-treatment-of-52020065.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-s-abbv-951-head-to-head-phase-3-study-i-52020068.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bardoxolone-a-new-oral-nrf2-activator-applie-52020069.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/wegovy-semaglutide-2-4mg-significantly-con-52025062.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/evobrutinib-the-first-btk-inhibitor-to-reduce-52029395.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-bayer-initiates-a-new-phase-3-study-of-v-52029397.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/jardiance-enpagliflozin-shows-sustained-hear-52029650.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ozawade-pitolisant-was-approved-by-the-europ-52037350.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/otsuka-pharmaceutical-deltyba-dilamani-52044148.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-s-ridgeback-oral-antiviral-drug-molnupir-52044150.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/vutrisiran-18-month-new-data-effective-treatm-52044151.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-s-first-complement-factor-b-inhibitor-52050864.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/opzelura-cream-enters-eu-review-the-first-top-52050865.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/novartis-first-complement-factor-b-inhibitor-52051776.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lumykras-sotorasib-is-about-to-be-approved-i-52052467.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/taiwanese-medicine-hua-pharmaceutical-besremi-53118267.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-eu-approves-pfizer-s-new-generation-of-ora-53118338.html 2021-12-31T04:24:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eli-lilly-s-head-to-head-study-begins-to-enrol-53118339.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/calquence-follow-up-data-for-3-years-the-risk-53118341.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-inhibitor-tavneos-is-about-to-be-approved-53118352.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-duvroq-daprodustat-significant-ef-53118358.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-c-type-natriuretic-peptide-a-53118450.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/targeted-immune-combination-cabometyx-tece-53118451.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merck-suspends-clinical-development-of-non-nuc-53118452.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/deucravacitinib-enters-the-review-in-the-unite-53118454.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/scemblix-new-data-efficacy-and-safety-continu-53118456.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/c3-targeting-inhibitor-empaveli-pegcetacoplan-53170302.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/rinvoq-upadacitinib-effective-in-patients-w-53170303.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-vanflyta-chemotherapy-first-line-t-53170305.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/ozempic-semaglutide-high-dose-2-0mg-is-about-53170311.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/kerendia-finerenone-started-a-phase-3-study-53193354.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/abbvie-oral-jak1-inhibitor-rinvoq-upadacitini-53196778.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-duvroq-daprodustat-significant-ef-53196911.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-c-type-natriuretic-peptide-a-53197014.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-nerlynx-neratinib-phase-2-clinical-53197019.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/bristol-myers-squibb-inhibitor-mavacamten-53198439.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/pioneering-sirna-cholesterol-lowering-drug-leq-53200525.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eu-approves-aspaveli-treatment-of-paroxysmal-53763348.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/syk-inhibitor-tavalisse-fatantinib-phase-3-s-53763352.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-inhibitor-xeljanz-tofacitinib-was-approv-53788718.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/amgen-s-lumykras-sotorasib-approved-by-the-e-53831216.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inhibitor-parsaclisib-the-total-remission-rat-53831218.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/eisai-and-gilead-sign-a-new-agreement-to-distr-53874178.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/rinvoq-applies-for-a-new-indication-the-treat-53925560.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-united-kingdom-approved-qinlock-ripretini-53925611.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/fda-approves-pfizer-s-next-generation-oral-jak-53941327.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/us-fda-granted-priority-review-for-topical-jak-53951936.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/u-s-fda-approves-abbvie-s-second-indication-f-54088371.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/lorviqua-lorlatinib-is-about-to-be-approved-54139438.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/hefei-home-sunshine-pharma-successfully-renewe-61883459.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-china-2023-shanghai-our-68192763.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-china-2023-guangzhou-ou-68192764.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/merry-christmas-and-a-happy-new-year-76689525.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/notice-on-spring-festival-holiday-in-76689526.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-china-2023-shanghai-our-76689527.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-28th-tine-tashkent-uzbekista-76689528.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-worldwide-europe-2024-mi-78233303.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/exhibition-record-of-uzbekistan-tihe-exhibitio-78233304.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/new-era-natural-health-exercise-79646307.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/the-new-oral-antibiotic-orlynvah-has-been-appr-84684339.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-china-2025-shanghai-our-17741239234356224.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/inflisiran-cas-1639324-58-5-series-intermed-17741239339131904.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/professional-supplier-of-specialized-resin-pro-17741239345734656.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-china-2026-shanghai-our-17776991729247232.html 2026-04-01T09:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/news/welcome-to-visit-cphi-worldwide-europe-2026-mi-17776992000549888.html 2019-11-15T15:10:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/development-status-of-raw-materials-41098352.html 2020-01-03T16:41:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-the-key-cause-of-t-cell-depletion-in-42824042.html 2020-06-18T11:08:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/lrrk2-in-1-cas-1234480-84-2-biological-activit-47057963.html 2020-06-17T15:20:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-risdiplam-significantly-improve-motor-f-47058072.html 2020-07-09T18:02:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-approves-fintepla-48770734.html 2020-06-10T16:08:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/colorectal-cancer-news-braf-v600e-mcrc-s-firs-47057849.html 2020-06-17T14:51:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-glofitamab-is-a-powerful-treatment-for-r-47057798.html 2020-06-17T14:27:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-new-generation-of-ophthalmic-drug-be-47056407.html 2020-06-10T16:27:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/evrenzo-rosastat-is-a-non-inferior-phase-iii-47056406.html 2020-06-17T16:05:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-astrazeneca-hypoglycemic-drug-farxiga-sign-47056366.html 2020-06-24T13:47:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/myovant-oral-gnrh-receptor-antagonist-relugoli-47056185.html 2020-06-10T16:31:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-dpp1-inhibitor-brensocatib-47056184.html 2020-09-01T11:05:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/better-than-pfizer-s-bosutinib-novartis-oral-49467986.html 2020-06-17T14:56:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-btk-inhibitor-calquence-monotherap-47056183.html 2020-06-17T14:48:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/another-neulasta-biosimilar-drug-approved-for-47056182.html 2020-06-17T14:44:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-tivicay-pd-dotelavir-disp-47056181.html 2020-05-14T10:16:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/where-did-the-new-drug-development-go-against-46568597.html 2020-06-03T16:04:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-s-oral-s1p-receptor-modul-46472459.html 2020-05-21T10:01:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-awarded-ilixadencel-advanced-regene-46362544.html 2020-05-27T11:17:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-bms-star-immune-combination-opdivo-yervo-46359153.html 2020-06-10T04:59:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-multiple-sclerosis-drug-z-46359113.html 2020-06-03T14:38:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/opdivo-yervoy-combined-chemotherapy-received-f-46358746.html 2020-06-03T15:22:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-cyramza-and-erlotinib-combination-th-46355632.html 2020-05-14T10:13:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/how-to-save-the-chaotic-biological-clock-scie-46353434.html 2020-06-02T18:10:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-intravenous-injection-of-artes-46353340.html 2020-05-20T18:10:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-capmatinib-approved-to-treat-nsclc-do-46349869.html 2020-06-02T18:16:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sanofi-regeneron-dupixent-approved-in-the-unit-46349749.html 2020-05-14T10:19:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-gsk-anti-inflammatory-drug-nucala-iii-has-46349728.html 2020-05-14T10:26:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/regeneration-yuan-and-zaiding-pharmaceutical-r-46342815.html 2020-05-08T09:51:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bms-s-first-erythrocyte-maturation-agent-reblo-46342639.html 2020-06-03T15:16:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-oriahnn-is-approved-by-the-us-fda-the-46342284.html 2020-05-20T18:13:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/uk-nice-approves-roche-kadcyla-for-early-breas-46342138.html 2020-05-27T11:43:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/hisun-s-favivir-tablets-are-fully-supplied-to-46342086.html 2020-05-14T10:29:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-eylea-abercept-pre-filled-syringes-are-46341990.html 2020-05-14T10:23:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/acceleron-bms-tgf-ligand-trap-soterercept-46341989.html 2020-05-15T10:52:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-granted-2-fast-track-qualifications-for-so-46341988.html 2020-06-09T15:18:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/enhertu-developed-by-az-daiichi-sankyo-is-ap-46341987.html 2020-05-08T09:38:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/viralym-m-an-allogeneic-multivirus-specific-t-46341986.html 2020-06-02T18:05:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/67-of-patients-have-significantly-improved-sy-46341985.html 2020-06-09T15:18:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/south-korea-s-sk-biopharmaceutical-xcopri-cen-46341983.html 2020-05-15T11:08:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-multiple-sclerosis-drug-sinimod-table-46327099.html 2020-05-21T14:19:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/interview-with-mr-wang-lei-executive-vice-pr-46327098.html 2020-05-21T09:55:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/otezla-the-oral-anti-inflammatory-drug-acquir-46327097.html 2020-05-21T13:31:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/myokardia-innovative-oral-cardiomyopathy-targe-46327096.html 2020-06-02T18:04:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zhong-nanshan-li-lanjuan-zhang-boli-s-latest-46326886.html 2020-06-09T09:52:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-nuclear-export-inhibitor-xpovio-subm-46326885.html 2020-06-02T18:07:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-best-in-class-calcineurin-inhibitor-vo-46326884.html 2020-06-09T09:52:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-s-unlimited-cancer-species-targeting-dru-46326883.html 2020-06-03T14:40:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/alzheimer-s-disease-imaging-diagnosis-breakthr-46326882.html 2020-06-03T14:49:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-domestic-btk-inhibitor-zebutinib-wil-46326881.html 2020-05-15T10:53:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-jelmyto-mittomycin-with-46326879.html 2020-06-03T15:04:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-sirturo-bedaquiline-pediat-46326877.html 2020-05-27T11:38:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/1-long-term-injection-of-cabotegravir-defeated-46303070.html 2020-09-30T11:21:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/a-new-class-of-hypoglycemic-drug-imeglimin-un-50450271.html 2020-10-12T14:54:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-first-line-long-term-survival-data-f-50450272.html 2020-05-27T11:13:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-pf-06939926-latest-data-protein-stable-46302912.html 2020-06-03T16:07:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-rozlytrek-is-about-to-be-approved-by-the-46302911.html 2020-06-03T15:27:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-anti-inflammatory-drug-taltz-was-a-46302910.html 2020-06-03T14:34:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-multiple-sclerosis-drug-z-46302909.html 2020-05-27T11:49:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/evarenzo-astellas-evrenzo-rosastat-entered-46302908.html 2020-06-02T18:13:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astellas-vesicare-solinaxin-succinate-oral-s-46302907.html 2020-06-03T15:33:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-brinlinta-ticagrelor-was-approve-46302906.html 2020-05-08T09:41:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-new-hyperkalemia-drug-lokelma-wa-46302905.html 2020-05-07T15:19:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-bristol-myers-squibb-opdivo-yervoy-combi-45468761.html 2020-05-07T15:31:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-venclyxto-gazyvaro-fixed-course-witho-45468666.html 2020-04-30T16:41:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-opdivo-odivo-received-the-firs-45395603.html 2020-10-22T09:46:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-jak1-inhibitor-phase-2b-3-clinical-resu-50809514.html 2020-10-26T13:41:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-antibody-cocktail-therapy-azd7442-50812092.html 2020-05-10T22:22:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-s1p1-regulator-ponesimod-app-45381881.html 2020-05-07T09:39:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-s1p1-regulator-ponesimod-app-45364630.html 2020-05-10T05:18:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sihuan-pharmaceutical-acquires-all-rights-and-45364538.html 2020-05-10T05:14:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vir-s-sirna-drug-vir-2218-administered-subcuta-45364365.html 2020-05-07T09:33:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sanofi-cablivi-is-approved-by-canada-for-the-t-45364262.html 2020-04-30T16:53:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-trulicity-is-approved-by-the-us-fda-45364208.html 2020-05-07T09:19:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cd19-targeting-new-fc-optimized-immune-enhanci-45364154.html 2020-05-07T14:52:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ror1-targeted-monoclonal-antibody-cirmtuzumab-45343669.html 2020-05-07T13:58:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-oral-proteasome-inhibitor-ninlaro-ixaz-45343666.html 2020-11-10T09:58:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/kalydeco-is-approved-by-the-european-union-it-51541524.html 2020-05-09T15:11:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/targeting-ccr5-to-treat-new-coronavirus-pneumo-45343575.html 2020-05-09T15:05:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-s-anti-inflammatory-drug-ste-45343330.html 2020-05-07T09:46:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-imfinzi-infineon-single-drug-a-45343263.html 2020-04-30T16:30:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rocre-s-multiple-sclerosis-drug-ocrevus-signif-45343162.html 2020-05-09T14:57:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nemolizumab-treatment-of-nodular-pruritus-pn-45343117.html 2020-04-29T08:54:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/immunity-dopamine-may-be-the-culprit-in-child-45343116.html 2020-05-09T14:57:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-cosentyx-is-approved-by-the-european-45342974.html 2020-05-09T14:57:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/independent-research-and-development-of-antide-45342972.html 2020-05-09T14:55:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ono-pharmaceutical-s-braftovi-three-drug-progr-45342971.html 2020-05-09T14:51:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/anti-cancer-drug-rozlytrek-approved-in-japan-f-45342871.html 2020-05-09T14:18:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-world-s-first-iron-carrier-cephalosporin-f-45341479.html 2020-05-08T19:26:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/mylan-pakang-myl-1402-bevacizumab-biosimila-45306773.html 2020-05-08T19:26:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-third-indication-for-otezla-a-blockbuster-45306720.html 2020-05-07T16:24:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-next-generation-jak1-inhibitor-abroci-45306716.html 2020-05-08T19:23:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ascentage-pharma-apg-2575-global-phase-ib-ii-45306611.html 2020-05-07T16:15:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oral-mpo-inhibitors-are-eligible-for-fda-fast-45306606.html 2020-05-08T19:26:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-s-epclusa-bentongsha-is-approved-by-t-45306479.html 2020-04-30T17:24:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-alunbrig-s-new-indication-enters-the-pr-45306037.html 2020-05-07T10:10:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-maviret-aino-is-approved-by-the-europ-45306035.html 2020-05-08T18:48:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-risdiplam-significantly-improves-the-sur-45305899.html 2020-05-08T18:48:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cell-challenge-the-textbook-reveal-the-mecha-45305898.html 2020-04-29T08:50:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/stm-genetic-modification-of-stem-cells-can-im-45305892.html 2020-05-08T18:15:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/alks3831-olanzapine-samidorphan-phase-iii-45305402.html 2020-05-07T15:45:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/epidyolex-europe-applies-for-new-indications-f-45287064.html 2020-05-07T16:17:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/multi-system-atrophy-new-drug-fda-granted-the-45287063.html 2020-05-07T16:42:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-pioneering-sirna-cholesterol-lowerin-45287032.html 2020-05-07T16:38:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-parp-inhibitor-lynparza-is-quali-45287031.html 2020-05-07T11:18:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jama-s-latest-analysis-the-median-r-d-cost-45287030.html 2020-04-29T09:15:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nat-commun-brain-scientists-delve-into-the-me-45286996.html 2020-05-07T13:43:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/three-in-one-capsule-talicia-omeprazole-amo-45286991.html 2020-05-07T15:24:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-boehringer-lilly-sglt2-in-45286990.html 2020-04-30T17:10:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/covid-19-detection-tips-45286989.html 2020-04-29T09:10:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-a-major-breakthrough-in-parkinson-s-di-45286988.html 2020-05-07T11:06:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-therapeutic-effect-of-narsoplimab-on-trans-45286937.html 2020-04-30T17:15:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-new-anti-epileptic-drug-from-plant-c-45286936.html 2020-01-20T15:26:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/consumption-of-trans-fatty-acids-may-increase-45286935.html 2020-05-08T09:28:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-jak-inhibitor-anti-inflammatory-dr-45286850.html 2020-05-08T09:20:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nurtec-odt-the-first-cgrp-receptor-antagonist-45286849.html 2020-05-07T13:49:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-global-supply-of-hiv-drug-kreizil-lop-45286847.html 2020-05-07T15:37:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sglt2-inhibitor-receives-fda-fast-track-qualif-45286846.html 2020-05-07T14:00:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-s-egfr-met-bispecific-antibo-45286845.html 2020-05-08T09:23:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/j-neurosci-dopamine-may-regulate-sex-differen-45286844.html 2020-04-29T09:03:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cell-rep-the-mechanism-of-action-of-dopamine-45286841.html 2020-05-08T09:25:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-opdivo-is-approved-for-th-45286765.html 2020-05-08T09:23:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-multi-kinase-kinase-inhibitor-ofev-45286760.html 2020-05-08T09:25:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-world-s-second-rnai-drug-givlaari-is-appro-45286758.html 2020-05-08T09:23:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-and-ideaya-sign-clinical-r-d-cooperat-45286757.html 2020-05-07T10:13:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zhimeng-pharmaceutical-is-researching-hbv-caps-45286756.html 2020-05-08T09:23:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-the-first-intravenous-anal-45286755.html 2020-05-08T09:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/apg-2575-has-obtained-three-clinical-licenses-45286753.html 2020-05-08T09:18:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cinda-bio-s-fgfr-inhibitor-pemigatinib-registe-45286752.html 2020-04-30T16:33:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-s-first-unlimited-cancer-species-targete-45286751.html 2020-05-08T09:20:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-ace-biologic-rituxan-adds-a-new-indicati-45286750.html 2020-05-08T09:23:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/clin-cancer-res-the-key-to-breast-cancer-cell-45286749.html 2020-05-08T09:20:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nat-neurosci-key-genes-regulate-autism-and-ad-45286748.html 2020-05-07T15:34:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/strong-growth-effect-intramuscular-injection-c-45286671.html 2020-05-07T14:48:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/howerson-s-innovative-drug-almonertinib-tablet-45286669.html 2020-05-08T09:20:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-isturisa-osilodrostat-t-45286668.html 2020-05-08T09:23:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-publishes-q-a-guides-on-related-product-45286667.html 2020-05-08T09:20:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cancer-cell-new-discovery-acute-myeloid-leuk-45286665.html 2020-05-08T09:15:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ajhg-new-study-reveals-effects-of-pten-mutati-45286664.html 2020-05-08T09:15:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/neuron-the-yin-yang-side-of-dopamine-45286663.html 2020-05-07T14:25:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-fiasp-fast-acting-insulin-aspart-45286662.html 2020-05-08T09:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/adrecizumab-s-phase-2-proof-of-concept-study-i-45286660.html 2020-01-20T15:22:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/commun-biol-special-protein-in-brain-may-help-45286659.html 2020-05-08T09:20:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-9-biosimilars-approved-by-the-us-fda-are-a-45286658.html 2020-05-08T09:20:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-drug-naizilai-granules-approved-for-clinic-45286657.html 2020-05-07T11:36:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tetaxipu-global-original-innovative-drugs-fro-45286585.html 2020-05-08T09:25:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-cluster-headache-medicine-eli-lilly-45286578.html 2020-05-08T09:23:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gsk-strong-growth-effect-intramuscular-injec-45286576.html 2020-05-08T09:25:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-new-generation-s1p-receptor-modulato-45286575.html 2020-04-29T08:57:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/elife-long-term-setbacks-will-inhibit-the-pro-45286574.html 2020-05-08T09:20:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-the-first-sustained-releas-45286571.html 2020-05-08T09:23:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tg6002-treatment-of-liver-metastasis-colorecta-45286570.html 2020-05-07T10:18:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/yoshino-iron-carrier-cephalosporin-fetcroja-c-45286569.html 2020-05-08T09:23:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-lilly-tanezumab-entered-the-review-in-45286568.html 2020-05-08T09:15:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cell-reports-how-does-dopamine-tell-you-that-45286567.html 2020-05-08T09:20:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/india-approves-ppar-dual-agonist-for-the-first-45286566.html 2020-01-20T14:11:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/science-journal-pancreatitis-is-actually-a-st-45286559.html 2020-05-08T09:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-glaxosmithkline-parp-inhibitor-zejula-zer-45286558.html 2020-05-08T09:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-promoting-il-17a-production-could-impr-45286557.html 2020-05-08T09:13:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/science-reveals-nerve-cell-types-associated-w-45286555.html 2020-05-08T09:23:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/karyopharm-s-first-nuclear-export-inhibitor-xp-45286554.html 2020-05-08T09:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/axsome-s-new-oral-multi-mechanism-drug-axs-45286553.html 2020-05-08T09:23:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oral-rock2-inhibitor-kd025-treatment-after-2-m-45286552.html 2020-05-08T09:20:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/alnylam-s-highly-innovative-drug-givlaari-is-a-45286551.html 2020-05-08T09:18:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/valtoco-diazepam-nasal-spray-the-first-nasa-45286550.html 2020-05-08T09:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/neurology-shocked-not-sleeping-for-one-night-45286549.html 2020-05-08T09:20:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/j-med-chem-hiv-drug-efavirenz-could-potential-45286548.html 2020-05-08T09:13:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-potent-farnesyl-transferase-inhibitor-tipi-45286547.html 2020-05-08T09:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/science-how-does-dopamine-cause-cocaine-addic-45286546.html 2020-05-08T09:23:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/science-journal-reveals-thrombin-and-platelet-45286545.html 2020-04-30T16:15:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sitting-and-watching-tv-for-a-long-time-will-a-45286543.html 2020-01-06T17:10:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/combination-of-antiangiogenic-drugs-and-cancer-42793355.html 2020-01-03T13:58:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/science-increasing-collagen-affinity-improves-42793274.html 2020-01-17T05:45:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nicotinamide-mononucleotide-nmn-production-42793158.html 2020-01-03T17:18:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-application-of-human-neural-stem-cells-alz-42767092.html 2020-01-15T11:18:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ready-to-use-car-t-therapy-an-expedient-or-a-42767091.html 2020-01-16T13:01:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/phase-iii-clinical-success-of-akari-complement-42766798.html 2020-01-15T10:46:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sintilimab-achieves-primary-study-endpoint-in-42766742.html 2020-01-16T12:57:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/study-on-the-mechanism-of-nad-regulating-plant-42766741.html 2020-01-15T09:25:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-reveals-section-clocks-that-regulate-h-42766736.html 2020-01-07T14:59:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/study-explores-emerging-role-of-nad-in-innate-42747410.html 2020-01-07T14:23:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/history-synthesis-and-function-of-nad-nic-42747408.html 2020-01-06T17:40:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/azz-pharma-new-recombinant-erwinia-asparaginas-42747405.html 2020-01-16T00:12:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nat-cell-biol-scientists-successfully-cultiva-42747307.html 2020-01-16T00:12:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-preparation-method-of-protein-aie-nano-poi-42747306.html 2020-01-02T17:31:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/functions-of-coenzyme-q10-42747062.html 2019-11-29T01:32:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/biomedical-engineering-industry-41128739.html 2019-11-15T15:02:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/drug-supplies-41119597.html 2019-11-15T15:16:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fine-chemical-characteristics-41119559.html 2019-11-15T15:17:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fine-chemical-classification-41079617.html 2019-11-27T05:52:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/introduction-to-fine-chemicals-41079616.html 2019-11-27T05:48:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/prospects-for-the-development-of-apis-41079390.html 2019-11-27T05:44:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/o-chlorobenzoic-acid-41079376.html 2019-11-15T15:14:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/current-status-of-fine-chemical-industry-41079300.html 2019-11-27T05:48:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/classification-of-apis-41079299.html 2019-11-27T05:48:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/medical-development-41079298.html 2019-11-15T15:07:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/industry-scale-of-medicine-41079272.html 2019-11-15T15:13:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/production-of-apis-41079271.html 2019-11-27T05:48:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pharmaceutical-industry-41079201.html 2019-11-15T15:05:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fluorinated-pyridine-41079175.html 2019-11-27T05:46:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/classification-of-medicine-41079109.html 2019-11-27T05:46:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/medical-introduction-41079108.html 2019-11-27T05:44:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/status-of-lactams-41079107.html 2019-11-15T15:06:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/what-is-biphenoldiol-41079078.html 2019-11-27T05:46:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/lactam-gap-41079077.html 2020-08-17T16:19:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/next-generation-selective-immunomodulator-imu-49107133.html 2020-08-17T16:10:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ppar-agonist-seladelpar-phase-iii-clinical-su-49105476.html 2020-08-25T09:10:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/chi-med-sofatinib-in-the-treatment-of-neuroend-49096716.html 2020-08-17T15:32:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-eu-approves-pretomanid-to-treat-highly-dru-49092799.html 2020-08-17T15:25:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-pharmaceuticals-a-drug-under-developmen-49092435.html 2020-08-17T15:52:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zai-lab-ripretinib-was-included-in-the-priorit-49092433.html 2020-08-17T16:30:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-ingelheim-ofev-nintedanib-signifi-49088819.html 2020-08-17T16:03:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-world-s-first-hepatitis-d-treatment-drug-49088815.html 2020-07-17T18:26:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/otsuka-anticancer-drug-inqovi-cedazuridine-48771218.html 2020-07-09T17:25:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/brensocatib-phase-ii-clinical-significantly-r-48771217.html 2020-07-09T17:43:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-axl-kinase-inhibitor-bemcentinib-com-48771088.html 2020-07-20T14:55:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/two-pfizer-biontech-mrna-vaccines-under-develo-48770965.html 2020-07-20T15:09:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/baoyuan-pharmaceutical-and-south-korea-s-newg-48770948.html 2020-07-10T17:10:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/glaxosmithkline-s-hif-ph-inhibitor-duvroq-dap-48770869.html 2020-07-20T15:24:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-ingelheim-ofev-nintedanib-is-appr-48770749.html 2020-07-17T18:20:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/europe-s-first-biosimilar-for-insulin-aspart-48770741.html 2020-07-10T17:07:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ultomiris-new-indication-is-approved-by-the-e-48770739.html 2020-07-10T16:54:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sarepta-s-third-exon-jump-therapy-casimersen-a-48770493.html 2020-07-17T18:30:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-grants-new-deuterated-jak1-2-inhibito-48770061.html 2020-07-17T18:36:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/biogen-submits-application-for-listing-of-alca-48770060.html 2020-07-09T17:40:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-fintepla-fenfluramine-ora-48769996.html 2020-07-09T18:05:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vertex-s-innovative-triple-therapy-kaftrio-eu-48769995.html 2020-07-17T18:33:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-mercapto-lynparza-received-eu-appr-48769842.html 2020-07-17T18:39:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-finerenone-phase-iii-clinical-success-s-48769841.html 2020-07-17T18:28:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-laba-lama-ics-product-enerzair-breezh-48767946.html 2020-08-17T12:08:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/simcere-pharmaceuticals-signed-an-exclusive-li-48767465.html 2020-08-17T12:08:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-rozlytrek-is-approved-in-the-eu-treat-n-48767464.html 2020-08-05T18:05:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-third-phase-iii-study-of-abbvie-s-oral-jak-48767463.html 2020-08-06T09:46:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-s-oral-cgrp-receptor-antagonist-atogepa-48767462.html 2020-08-06T09:58:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-lilly-s-sglt2-inhibitor-jardiance-48767461.html 2020-08-06T09:51:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-pharmaceuticals-avapritinib-was-include-48767460.html 2020-08-17T12:08:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/he-us-fda-granted-merck-s-hif-2-inhibitor-mk-48767459.html 2020-07-24T11:02:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-second-phase-iii-study-of-abbvie-s-oral-ja-48767458.html 2020-08-06T09:36:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/breast-cancer-precision-medicine-novartis-pi-48767457.html 2020-08-17T12:08:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-european-union-approves-xenleta-lefamulin-48767456.html 2020-07-20T14:57:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/janssen-tremfya-the-first-il-23-inhibitor-for-48767455.html 2020-08-05T18:14:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-chi-med-met-inhibitor-savolitinib-was-incl-48767454.html 2020-08-17T12:08:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-breztri-aerosphere-budi-gefu-h-48767453.html 2020-07-20T15:35:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-brilinta-aspirin-the-first-dual-48767452.html 2020-07-20T15:48:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-s-bayer-s-first-sgc-stimulant-vericiguat-48767451.html 2020-07-20T15:53:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/terlipressin-was-approved-by-the-us-fda-commit-48767450.html 2020-08-12T18:07:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-has-given-priority-to-reviewing-het-48767449.html 2020-08-05T10:14:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-the-unique-cationic-hydrox-48767448.html 2020-08-17T12:08:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-jakafi-ruxolitinib-successfully-tre-48767447.html 2020-08-17T12:08:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-drug-for-diabetic-foot-neuralgia-qutenza-48767446.html 2020-08-05T10:08:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-best-in-class-calcineurin-inhibitor-vo-48767445.html 2020-08-05T10:19:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/dojolvi-is-launched-in-the-united-states-the-48767444.html 2020-07-24T10:56:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zai-lab-s-china-listing-application-for-ripret-48767443.html 2020-08-05T10:28:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-wynzora-calccipotriol-bet-48767442.html 2020-07-24T11:00:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/daiichi-sankyo-prasugrel-is-better-than-clopid-48767441.html 2020-08-05T10:21:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-approves-the-marketing-of-innovative-narco-48767440.html 2020-07-09T18:07:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-long-acting-growth-hormone-transcon-hg-48767435.html 2020-07-09T17:16:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cancer-vitamin-d-can-open-the-protective-umbr-48767434.html 2020-06-24T13:27:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-pi3k-akt-pathway-inhibitor-ipatasertib-p-47058295.html 2020-06-10T16:35:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-third-indication-of-boehringer-ingelheim-o-47058294.html 2020-06-29T19:35:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/treatment-of-aggressive-lymphoma-fda-accelerat-47058224.html 2020-06-29T19:33:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-european-union-approves-fluad-quadrivalent-47058132.html 2020-06-29T19:32:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-s1p-receptor-modulator-re-47058081.html 2020-06-24T11:40:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/epizyme-epigenetics-drug-tazverik-has-been-app-47058079.html 2020-06-24T13:35:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fruquintinib-gets-fda-fast-track-qualification-47057941.html 2020-06-17T15:02:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-glp-1-agonist-semaglutide-weight-47057939.html 2020-06-29T19:27:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-world-s-first-iron-carrier-cephalosporin-f-47057853.html 2020-08-17T18:06:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/betta-pharma-ensartinib-first-line-treatment-49111586.html 2021-04-09T13:42:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/neuron-analyze-the-brain-s-switch-to-control-57414061.html 2020-08-17T15:37:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-and-korea-american-pharmaceuticals-signe-49112642.html 2020-06-17T14:40:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-s-gardasil-9-was-approved-by-the-us-fda-47057505.html 2020-06-24T11:37:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-s-first-phase-iii-study-of-oral-jak-inh-47057395.html 2020-06-24T11:44:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/beigene-s-application-for-zebutinib-listing-in-47057394.html 2020-06-24T15:45:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-lilly-sglt2-inhibitor-jardiance-em-47057392.html 2020-05-20T18:04:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/four-key-elements-and-development-trends-of-ad-47057292.html 2020-06-10T15:06:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-s-oral-jak1-inhibitor-rinvoq-submitted-47057291.html 2020-06-17T15:04:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-glp-1-agonist-semaglutide-loss-ph-47057290.html 2020-06-10T15:00:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-il-17a-inhibitor-won-the-5th-fda-a-47057289.html 2020-06-17T14:37:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-abbvie-venclexta-azacitidine-phase-iii-47057288.html 2020-06-24T11:30:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/xi-an-janssen-releases-4-years-clinical-data-o-47057287.html 2020-06-10T15:01:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/treatment-of-specific-lung-cancer-eli-lilly-s-47057286.html 2020-08-25T10:42:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/protalix-casey-s-long-acting-galactosidase-a-49463915.html 2020-09-01T11:29:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-lilly-jardiance-empagliflozin-sig-49463920.html 2020-08-25T13:40:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-ingelheim-ofev-nintedanib-launche-49465685.html 2020-09-01T10:52:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-the-first-cysteamine-eye-d-49466204.html 2020-09-01T11:16:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/winlevi-cream-a-local-androgen-receptor-inhib-49473690.html 2020-09-01T11:25:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-s-first-complement-factor-b-inhibitor-49473691.html 2020-09-01T11:13:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/glaxosmithkline-blenrep-was-approved-by-the-eu-49475209.html 2020-09-04T20:36:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sub-journal-of-nature-repair-the-heart-small-49477775.html 2020-09-04T20:36:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-lenvima-lenvatinib-post-marketing-stud-49477787.html 2020-08-25T13:49:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-abbvie-venclexta-azacitidine-phase-iii-49477963.html 2020-09-04T20:47:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-stamp-inhibitor-asciminib-phase-iii-e-49478423.html 2020-08-25T10:21:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/real-world-retrospective-research-giotag-afat-49478514.html 2020-09-08T12:07:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-tepotinib-the-world-s-first-met-inhibit-49745276.html 2020-09-08T11:45:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-unlimited-cancer-species-precision-49745279.html 2020-09-15T13:45:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/glaxosmithkline-s-new-oral-hif-ph-inhibitor-du-49745282.html 2020-09-08T13:41:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-and-powerful-aak1-inhibitor-lx9211-ent-49745453.html 2020-09-08T11:54:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-the-ret-inhibitor-gavreto-49757971.html 2020-09-08T11:37:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-eli-lilly-s-glp-1ra-hypogl-49758144.html 2020-09-08T11:57:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-s-ret-inhibitor-pratinib-has-been-accep-49758145.html 2020-09-08T13:38:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-third-generation-of-potent-comt-inhibitor-49772082.html 2020-09-22T17:47:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/phase-iii-clinical-success-of-ganachone-for-ra-50126902.html 2020-09-22T09:09:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-reyvow-has-positive-clinical-results-50126903.html 2020-09-22T17:56:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-and-amgen-join-forces-produce-neutr-50126904.html 2020-09-22T09:25:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/terlipressin-was-rejected-by-the-us-fda-and-ha-50126905.html 2020-09-22T18:06:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-efficacy-of-bristol-myers-immunization-com-50126906.html 2020-09-15T14:31:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-next-generation-immunomodulator-imu-838-q-50126907.html 2020-09-22T09:04:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-reyvow-has-positive-clinical-results-50126908.html 2020-09-22T17:44:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/another-major-deal-for-antibody-drug-conjugate-50138096.html 2020-09-28T21:43:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-s-non-steroidal-androgen-receptor-antago-50138097.html 2020-09-29T14:48:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-mayzent-improves-cognition-slows-do-50158712.html 2020-09-22T17:54:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/heat-shock-inducer-arimoclomol-has-been-review-50158714.html 2020-09-22T09:39:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-incyte-oral-jak-inhibitor-olumiant-50158897.html 2020-09-15T14:10:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/can-treat-asthma-and-copd-at-the-same-time-gs-50158898.html 2020-09-22T10:06:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/another-major-deal-for-antibody-drug-conjugate-50158909.html 2020-09-29T14:55:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-and-dogma-reached-an-agreement-to-50158910.html 2020-09-22T09:48:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/another-major-deal-for-antibody-drug-conjugate-50159049.html 2020-09-15T14:41:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vertex-s-innovative-triple-therapy-trikafta-su-50186106.html 2020-09-15T14:36:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fintepla-fenfluramine-in-the-treatment-of-dr-50187179.html 2020-09-22T17:45:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/shorten-patient-recovery-time-jak-inhibitor-re-50212184.html 2020-09-30T09:48:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-xalkori-has-been-reviewed-by-the-us-fda-50441274.html 2020-10-12T15:41:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/otsuka-s-topical-pde4-inhibitor-difamilast-app-50441275.html 2020-10-12T16:21:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-world-s-first-photoimmunotherapy-drug-is-a-50441276.html 2020-10-12T14:58:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pacritinib-applied-for-listing-treatment-of-m-50441277.html 2020-09-30T11:47:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ayvakyt-avapritinib-was-approved-by-the-euro-50441278.html 2020-09-30T11:42:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/a-new-class-of-hypoglycemic-drug-imeglimin-un-50450895.html 2020-09-30T11:11:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-fycompa-perampanel-is-recommended-and-50461806.html 2020-10-14T23:15:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/natural-drug-genkwadaphnin-can-block-cholester-50461814.html 2020-10-12T15:51:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/researchers-have-developed-a-btk-kinase-inhibi-50462369.html 2020-10-12T15:47:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approved-alkindi-sprinkle-to-treat-pedi-50473881.html 2020-10-12T15:45:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-s-uptravi-intravenous-prepar-50474089.html 2020-10-12T15:31:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-fosdenopterin-priority-revi-50474097.html 2020-09-30T11:57:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/daiichi-sankyo-enhertu-is-approved-it-signifi-50482682.html 2020-10-26T12:03:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pacritinib-will-be-on-the-market-in-2021-trea-50808635.html 2020-10-22T10:00:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/shionoyi-s-world-s-first-siderophore-cephalosp-50808797.html 2020-10-26T12:22:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/otsuka-v2-receptor-antagonist-opc-61815-phase-50809509.html 2020-10-20T16:03:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zelgen-pharmaceutical-s-application-for-a-new-50817646.html 2021-09-13T17:47:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-eu-granted-accelerated-evaluation-of-ganax-62065321.html 2021-09-13T17:17:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-xarelto-rivaroxaban-as-62065322.html 2021-08-20T18:00:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-expands-incyte-lilly-jak-inhibitor-ol-62065323.html 2020-10-26T15:56:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-pi3k-inhibitor-aliqopa-combined-with-rit-50818073.html 2020-11-04T11:48:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-paliperidone-palmitate-long-51540958.html 2020-10-28T15:59:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-veklury-remdesivir-was-approved-by-th-51540959.html 2020-11-04T11:39:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/clofenac-meglumine-soft-capsule-breaking-the-p-51540961.html 2020-11-04T11:58:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-aimovig-the-first-phase-4-clinical-s-51540962.html 2020-11-10T10:18:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-s-acquisition-of-velosbio-the-first-ant-51540963.html 2020-11-17T10:50:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-mechanism-drug-nexletol-significantly-51540970.html 2020-11-17T10:30:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/glaxosmithkline-medicago-adjuvant-plant-derive-51541472.html 2020-11-10T09:40:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bms-original-deuterated-tyk2-new-drug-51542673.html 2020-11-17T10:38:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-s-super-flu-drug-xofluza-is-about-to-be-51542677.html 2020-11-17T10:27:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-side-effects-emerge-sanofi-alnylam-hemoph-51542701.html 2020-10-28T15:45:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-forxiga-dapagliflozin-is-about-51542702.html 2020-11-04T11:45:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gradual-frost-disease-is-expected-to-usher-in-51542752.html 2020-11-10T10:27:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-brilinta-ticagrelor-was-approved-51542820.html 2020-10-28T15:54:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-rinvoq-submitted-a-new-indication-appli-51549907.html 2020-10-28T16:13:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-s-potent-and-selective-factor-b-inhib-51549908.html 2020-11-10T10:13:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/lynparza-approved-in-the-eu-treatment-of-brca-51550060.html 2020-11-04T11:32:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/arikayce-is-approved-in-the-eu-the-first-drug-51550681.html 2020-11-10T10:24:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-forxiga-dapagliflozin-approved-51555652.html 2020-11-04T10:54:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/scientists-synthesize-new-antibiotics-through-51555654.html 2020-11-17T10:22:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-abrocitinib-in-the-treatment-of-sever-51561820.html 2020-10-28T15:48:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/egfr-targeted-drug-cures-early-stage-lung-canc-51561825.html 2020-10-28T15:52:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/roche-abbvie-venclexta-is-fully-approved-by-th-51561873.html 2020-10-28T16:05:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/leo-pharma-enstilar-foam-has-a-long-term-treat-51566818.html 2020-11-26T06:42:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/amgen-s-new-cardiac-myosin-activator-omecamti-51570315.html 2020-11-10T10:31:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-oral-jak-inhibitor-xeljanz-tofacitin-51572746.html 2020-11-17T10:46:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-sirna-cholesterol-lowering-drug-leqv-51575453.html 2020-11-26T10:50:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tivicay-pd-dotegravir-dispersible-tablets-is-51576039.html 2020-11-04T11:11:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-daiichi-sankyo-enhertu-receives-pr-51580870.html 2020-12-25T14:17:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-merck-eisai-keytruda-lenvima-phase-3-confi-53282457.html 2021-01-07T11:28:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-and-myovant-sciences-collaborate-to-dev-53282458.html 2021-01-07T11:33:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-eu-submits-an-application-ozempi-53282459.html 2021-01-14T10:47:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-farxiga-dapagliflozin-has-rece-53282461.html 2020-11-25T11:26:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jardiance-empagliflozin-milestone-phase-3-cl-53282462.html 2020-11-25T11:35:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-has-been-granted-the-second-emergenc-53282463.html 2021-01-14T10:52:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-once-a-week-long-acting-drug-somatrog-53282662.html 2020-12-02T11:33:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-tepmetko-the-world-s-first-oral-met-inh-53282663.html 2020-11-25T11:14:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-cabotegravir-a-breakthrou-53282664.html 2020-11-25T11:45:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-zokinvy-the-first-farnesy-53282665.html 2020-12-11T15:05:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-lenvima-lenvatinib-post-marketing-stud-53282666.html 2020-12-15T14:39:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astellas-evrenzo-roxadustat-approved-in-ja-53282667.html 2020-12-15T14:17:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/kyprolis-darzalex-dexamethasone-three-drug-reg-53282669.html 2020-12-15T14:22:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/braf-v600e-mcrc-targeting-program-braftovi-tw-53282670.html 2020-12-15T15:08:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-blueprint-roche-gavreto-to-tre-53282694.html 2021-01-07T10:35:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bojian-plegridy-pegylated-interferon-1a-in-53282948.html 2020-12-11T15:20:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-tepmetko-the-world-s-first-oral-met-inh-53282949.html 2021-01-19T14:13:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/innovative-drug-orelabrutinib-was-approved-by-53282951.html 2021-01-07T11:03:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-third-generation-alk-inhibitor-lorbre-53283783.html 2021-01-14T10:10:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/acoladine-from-traditional-chinese-medicine-n-53283785.html 2020-12-11T15:08:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-viatris-pediatric-dolutegravir-53284502.html 2021-01-14T10:14:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/antengene-submits-selinexor-new-drug-listing-a-53284503.html 2020-12-02T11:47:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/soxgliflozin-treatment-of-heart-failure-result-53284504.html 2021-01-14T10:28:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/visen-pharmaceuticals-announces-approval-of-it-53284505.html 2020-11-25T11:29:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-inhibitor-lenacapavir-gs-6207-phase-53284844.html 2020-12-11T15:22:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/basilea-pfizer-cresemba-isavuconazole-was-ac-53284845.html 2020-12-15T14:52:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-hetlioz-tasimelteon-the-53284846.html 2020-12-15T15:01:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-approves-the-plasma-kallikrein-in-53284852.html 2020-12-25T13:48:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-pioneering-sirna-cholesterol-lowerin-53284854.html 2020-12-25T14:10:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-second-generation-oral-thrombopoietin-rece-53286602.html 2021-01-07T10:58:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-mersk-s-lynparza-olaparib-japan-53287280.html 2021-01-07T10:51:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/daiichi-sankyo-tarlige-mirogabalin-is-succes-53287504.html 2021-01-19T15:34:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approved-oxlumo-the-first-drug-to-trea-53287753.html 2021-06-22T15:01:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-nuzyra-omadacycline-for-62108754.html 2021-06-25T17:52:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-granted-tyvaso-dpi-treprostinil-dry-p-62109138.html 2020-12-02T11:16:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-roche-xofluza-for-people-53287754.html 2020-12-15T12:02:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sotagliflozin-treatment-of-heart-failure-resul-53287755.html 2021-01-19T15:34:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/glaxosmithkline-s-first-adhesion-inhibitor-ruk-53287765.html 2020-11-25T11:18:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-sanofi-rilzabrutinib-fast-53288066.html 2020-12-02T11:27:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/alkindi-sprinkle-is-launched-in-the-united-sta-53288067.html 2020-12-24T16:24:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-gip-glp-1-dual-receptor-agonist-ti-53288070.html 2020-12-02T11:25:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-viatris-pediatric-dolutegr-53288406.html 2020-11-25T11:08:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/c3-inhibitor-pegcetacoplan-receives-priority-r-53288411.html 2020-12-25T13:57:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-new-generation-therapy-beovu-2-phase-53293013.html 2021-01-19T17:11:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-novartis-the-breakthrough-53293014.html 2021-01-19T17:11:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bms-oral-s1p-receptor-modulator-zeposia-ozani-53293016.html 2020-12-25T14:00:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-jak2-inhibitor-inrebic-f-53293024.html 2020-12-25T14:07:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-eu-chmp-recommends-approval-of-sanofi-plav-53293265.html 2021-01-19T17:43:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-s-oral-jak-inhibitor-rinvoq-phase-3-cli-53295243.html 2020-12-11T15:10:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/alkindi-sprinkle-is-launched-in-the-united-sta-53297747.html 2021-01-07T11:09:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/hutchison-medicine-sofatinib-is-rolling-in-the-53300264.html 2021-01-07T10:33:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/parp-inhibitor-rubraca-treats-brca-mutant-ovar-53301909.html 2020-12-25T14:05:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-and-potent-aak1-inhibitors-obtained-fda-fa-53302444.html 2020-12-25T13:38:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-jak-inhibitor-in-the-treatment-of-ulcer-53308837.html 2021-01-07T10:55:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/peripheral-opioid-receptor-kor-agonist-kor-53310190.html 2020-12-02T11:37:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/basilea-pfizer-cresemba-isavuconazole-was-ac-53310884.html 2020-12-15T14:42:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-s-oral-tyrosine-kinase-inhibitor-cabome-53311064.html 2021-01-07T11:14:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zai-lab-cullinan-oncology-reached-an-exclusive-53314476.html 2020-12-25T14:29:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-powerful-kit-inhibitor-ayvakit-applied-for-53317789.html 2020-12-02T11:50:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/kyprolis-darzalex-dexamethasone-three-drug-reg-53318086.html 2020-11-25T11:39:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gsk-single-dose-krintafel-tafenoquine-is-eff-53318190.html 2021-01-21T11:33:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/xalkori-approved-in-the-united-states-the-fir-53917555.html 2021-01-29T17:21:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-approves-first-new-oral-drug-for-lupus-nep-53917556.html 2021-01-21T11:37:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/shiono-xofluza-was-approved-in-taiwan-china-53917557.html 2021-02-04T11:28:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/post-marketing-study-of-pfizer-xeljanz-in-the-53917558.html 2021-01-29T17:25:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-second-generation-oral-thrombopoietin-rece-53917559.html 2021-01-21T11:27:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astellas-mirabegron-has-been-reviewed-by-the-u-53917560.html 2021-02-04T10:35:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oral-gnrh-receptor-antagonist-relugolix-signif-53917561.html 2021-01-29T17:18:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-bayer-s-heart-failure-drug-vericiguat-re-53917562.html 2021-02-04T10:27:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-oral-pkr-allosteric-activator-mitabi-53917563.html 2021-01-29T17:30:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-usa-submits-an-application-ozemp-53917564.html 2021-02-04T10:41:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-btk-inhibitor-calquence-has-been-53917565.html 2021-02-04T17:46:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cabenuva-a-complete-long-acting-program-that-53917740.html 2021-02-04T10:54:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-announced-phase-2a-study-data-support-i-53917741.html 2021-01-29T17:23:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-approves-cabozantinib-combined-with-opdivo-53946018.html 2021-01-21T11:30:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-european-union-approves-tivicay-pd-dolute-53946019.html 2021-01-21T11:39:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-cd73-inhibitor-ab680-chemotherapy-anti-53946023.html 2021-02-08T10:03:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-sogroya-is-recommended-and-approv-54920911.html 2021-02-23T14:01:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-s-new-generation-androgen-receptor-inhib-54920915.html 2021-02-23T17:20:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/viiv-s-new-first-adhesion-inhibitor-rukobia-wa-54923044.html 2021-03-10T11:32:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/akeso-inc-pd-1-ctla-4-dual-antibody-for-treat-54923047.html 2021-02-08T10:00:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tagrisso-osimertinib-adjuvant-treatment-of-e-54923077.html 2021-03-10T11:37:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/front-microbio-the-probiotics-in-milk-will-ch-54923084.html 2021-02-23T16:51:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-invests-1-3-billion-us-dollars-to-54923091.html 2021-03-03T16:11:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-unique-cationic-hydroxybutyric-acid-therap-54923102.html 2021-03-17T15:26:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-jak-inhibitor-successfully-promotes-55444856.html 2021-03-17T15:44:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/peripheral-opioid-receptor-kor-agonist-kor-55444857.html 2021-03-25T14:20:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-data-from-merck-support-islatravir-implan-55444859.html 2021-03-25T14:20:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-acquires-an-iap-antagonist-for-nearly-55444864.html 2021-03-17T15:36:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-s-gefapixant-enters-the-review-in-the-un-55444865.html 2021-03-24T17:29:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/aveo-fotivda-tivozanib-has-been-approved-by-55445130.html 2021-03-17T15:33:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/an-imported-anti-inflammatory-drug-otezla-subm-55449538.html 2021-03-24T17:34:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-targeted-drug-tagrisso-osimerti-55455787.html 2021-03-24T17:30:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-kymriah-approved-treatment-of-2-type-55458830.html 2021-03-17T14:30:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-yescarta-has-been-approved-by-the-us-fd-55461100.html 2021-03-25T15:29:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nefecon-targeted-release-budesonide-applied-57385897.html 2021-04-01T16:18:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/inhibitor-rubraca-treatment-of-brca-mutant-ova-57385898.html 2021-05-17T13:39:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-approves-zegalogue-injection-to-treat-diab-57385899.html 2021-04-09T13:49:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cancer-research-high-fat-diet-can-cause-tumor-57385900.html 2021-04-01T16:59:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-inhibitor-lenvima-lenvatinib-has-been-57385901.html 2021-04-09T13:34:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/biol-sex-differ-supplementing-dha-in-the-diet-57385902.html 2021-12-23T15:36:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/livtencity-the-first-drug-used-for-the-treatm-65532527.html 2021-12-31T04:24:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-agonist-cobitolimod-in-the-treatment-of-mo-65532528.html 2021-12-31T04:24:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-hepcludex-bulevirtide-applied-for-lis-65532529.html 2021-12-23T15:39:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/livtencity-the-first-drug-used-for-the-treatm-65532530.html 2021-04-09T13:40:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/molecular-cancer-therapeutics-blocking-the-up-57385903.html 2021-05-17T13:39:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/green-tea-can-promote-the-recovery-of-gastric-57385904.html 2021-05-17T13:39:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astellas-gilteritinib-tablets-for-the-treatmen-57385905.html 2021-04-01T17:13:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-c3-inhibitor-amy-101-has-a-strong-effe-57385906.html 2021-04-15T13:53:52+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/orgovyx-relugolix-enters-censorship-in-the-e-57385907.html 2021-04-01T16:54:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-cll-drug-calquence-is-approved-b-57385908.html 2021-04-15T14:34:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pemazyre-pemigatinib-was-approved-by-the-eu-57385909.html 2021-04-15T14:18:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/maralixibat-has-been-reviewed-by-the-us-fda-as-57385910.html 2021-05-17T13:39:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-oral-therapy-receives-fda-breakthrough-the-57385911.html 2021-04-15T14:43:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/korsuva-kor-agonist-korsuva-enters-review-in-57385912.html 2021-04-27T13:59:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-grants-breakthrough-drug-designation-57385913.html 2021-05-17T13:39:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/innocare-obrutinib-is-approved-in-china-to-dev-57385914.html 2021-04-22T17:21:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-s-oral-jak1-inhibitor-rinvoq-s-new-indi-57385915.html 2021-05-08T16:11:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-egfr-targeting-drug-tagrisso-is-57385916.html 2021-04-27T14:02:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-sogroya-is-approved-by-the-europe-57385917.html 2021-05-17T13:39:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-targeted-drug-tagrisso-osimerti-57385918.html 2021-05-17T13:39:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-abandoned-erlead-apalutamid-57385919.html 2021-04-15T15:31:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-vyxeos-for-acute-myeloid-leuke-57385920.html 2021-05-08T16:35:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-kesimpta-reduce-the-risk-of-disabili-57385921.html 2021-03-25T14:16:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fruquintinib-sales-revenue-exceeds-200-million-57386642.html 2021-03-25T15:05:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/men-s-abuse-of-steroids-can-cause-long-term-im-57386643.html 2021-04-09T13:37:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/advanced-materials-new-technology-for-the-ins-57386644.html 2021-04-23T14:28:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/daiichi-sankyo-s-potent-and-selective-menin-in-57386645.html 2021-04-22T17:13:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-pharmaceuticals-avapritinib-was-approve-57386647.html 2021-04-22T17:57:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-approves-qelbre-viloxazine-for-atte-57386648.html 2021-04-22T17:00:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-tyvaso-treprostinil-the-57386649.html 2021-04-01T17:09:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/exelixis-and-merck-pfizer-reached-a-cooperatio-57386650.html 2021-05-08T16:51:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-eu-approved-the-third-indication-of-epidyo-57386651.html 2021-04-01T16:52:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-arcalyst-for-the-treatmen-57399823.html 2021-04-01T16:43:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-cardiac-myosin-allosteric-inhibi-57399824.html 2021-04-01T17:04:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oral-xenleta-outpatient-treatment-of-community-57399825.html 2021-04-01T16:38:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-maribavir-phase-3-clinical-success-wil-57399826.html 2021-03-25T15:08:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/spain-successfully-developed-a-new-type-of-nan-57401248.html 2021-04-23T14:26:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-and-celcuity-have-reached-a-partnership-57401249.html 2021-04-23T14:31:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/iterum-s-sulopenem-treatment-of-simple-urinary-57401250.html 2021-04-15T14:37:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-s-oral-cgrp-receptor-antagonist-atogepa-57401251.html 2021-04-27T14:23:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/buparlisib-completes-first-patient-dosing-in-g-57401252.html 2021-04-27T14:09:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-announces-data-on-the-efficacy-of-atr-in-57401253.html 2021-05-08T16:39:31+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sanofi-s-cd38-targeting-antibody-sarclisa-s-se-57401254.html 2021-05-08T16:25:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-evobrutinib-the-first-btk-inhibitor-to-57401255.html 2021-04-27T13:53:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/boehringer-ingelheim-bi456906-starts-phase-2-c-57414063.html 2021-05-19T16:17:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-koselugo-selumetinib-is-about-to-58061290.html 2021-05-19T15:51:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ann-rheum-dis-tenascin-c-can-promote-the-form-58061368.html 2021-05-19T16:20:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-targeted-drug-tagrisso-osimerti-58061369.html 2021-05-19T17:29:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ono-pharmaceutical-launched-adlumiz-anamoreli-58061370.html 2021-05-26T17:50:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sanofi-s-oral-serd-drug-amcenestrant-combined-58061372.html 2021-05-26T17:11:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/successful-phase-3-project-of-jak-inhibitor-ru-58061374.html 2021-06-03T22:55:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-announced-the-strong-efficacy-data-of-ha-58061378.html 2021-05-19T17:11:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-s-gavreto-pralsetinib-new-indication-58061538.html 2021-05-19T17:27:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-nefecon-budesonide-priori-58061540.html 2021-05-19T17:06:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/olamkicept-was-successful-in-the-treatment-of-58067284.html 2021-05-19T16:18:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-s-deucravacitinib-in-the-58067285.html 2021-06-04T02:41:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/imbruvica-venclexta-ibrutinib-venetoclax-th-58067358.html 2021-05-26T17:07:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/xarelto-rivaroxaban-aspirin-significantly-58067390.html 2021-05-26T17:54:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-abbvie-imbruvica-ibrutinib-58067458.html 2021-05-19T17:16:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-oral-nmda-receptor-antagonist-axs-58069339.html 2021-05-19T17:17:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bardoxolone-a-new-oral-nrf2-activator-is-und-58069342.html 2021-05-26T17:25:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/significant-progress-in-ten-years-of-radical-a-58069344.html 2021-05-19T17:22:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-mobocertinib-receives-priority-review-b-58069385.html 2021-06-04T04:18:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/amgen-otezla-has-strong-clinical-efficacy-in-t-58069853.html 2021-09-26T12:47:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/quorum-sensing-inhibitors-contribute-to-the-e-62064279.html 2021-06-21T17:43:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-myfembree-treatment-of-menorr-62064280.html 2021-06-22T14:52:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-pacritinib-priority-review-62064281.html 2021-09-26T12:47:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/combination-of-vs-6766-and-defactinib-total-r-62064282.html 2021-09-26T12:47:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/lenvima-keytruda-lenvatinib-pembrolizumab-sh-62064283.html 2021-06-22T14:19:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/inhibitor-derazantinib-in-the-treatment-of-int-62064284.html 2021-06-21T16:25:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bluebird-bio-skysona-is-about-to-be-approved-62064285.html 2021-06-25T17:41:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zuranolone-phase-3-clinical-success-taking-th-62064286.html 2021-06-21T16:40:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oral-s1p1-modulator-ponvory-ponesimod-approv-62064287.html 2021-06-25T17:36:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tabrecta-in-the-treatment-of-metex14-mutant-no-62064288.html 2021-06-22T15:22:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rinvoq-upadacitinib-treatment-for-more-than-62064289.html 2021-09-26T12:47:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rinvoq-is-about-to-be-approved-in-the-eu-for-i-62064290.html 2021-07-27T16:04:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jazz-oncology-drug-rylaze-is-approved-by-fda-f-62064291.html 2021-09-26T12:47:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/dapagliflozin-is-about-to-be-approve-62064292.html 2021-09-26T12:47:02+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-sub-publishes-another-breakthrough-in-c-62064293.html 2021-09-26T12:47:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vutrisiran-is-under-review-in-the-united-state-62064294.html 2021-07-30T10:48:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/evrenzo-roxadustat-suffered-three-setbacks-i-62064295.html 2021-07-27T11:13:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novo-nordisk-ozempic-semaglutide-the-hypogl-62064296.html 2021-09-26T12:47:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/all-5-studies-of-the-glaxosmithkline-hif-ph-in-62064297.html 2021-09-26T12:47:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-dayvigo-lemborexant-is-listed-in-hong-62064298.html 2021-09-26T12:47:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-lenacapavir-treats-patients-with-multi-62064299.html 2021-09-26T12:47:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/galapagos-announced-the-top-line-results-of-th-62064300.html 2021-07-30T11:08:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/galapagos-announced-the-top-line-results-of-th-62064302.html 2021-06-29T17:30:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/mitapivat-applies-for-listing-significantly-r-62064303.html 2021-09-26T12:47:11+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-approves-rezurock-the-first-rock2-in-62064317.html 2021-08-05T14:06:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-verquvo-vericiguat-has-been-approved-i-62065296.html 2021-09-26T12:57:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/klisyri-tirbanibulin-is-approved-in-the-eu-a-62065297.html 2021-08-05T10:56:23+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/skysona-the-first-gene-therapy-to-treat-cereb-62065298.html 2021-08-05T10:46:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-roche-abbvie-venclexta-v-62065301.html 2021-06-22T11:41:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fennec-company-pedmark-sodium-thiosulfate-re-62065302.html 2021-08-05T14:20:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-approved-octagam-10-the-first-intra-62065303.html 2021-06-22T11:55:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-ninlaro-ixazomib-was-approved-in-japa-62065304.html 2021-08-11T11:02:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-future-of-lantern-s-new-drug-can-be-expect-62065305.html 2021-06-21T17:31:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/zeposia-ozanimod-was-approved-by-the-us-fda-62065306.html 2021-08-11T11:11:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ck-274-phase-2-clinical-effect-remarkable-62065307.html 2021-08-11T11:24:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/winlevi-cream-a-topical-androgen-receptor-inh-62065308.html 2021-08-11T11:09:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/inhibitor-ck-274-phase-2-clinical-effect-is-re-62065309.html 2021-09-26T12:57:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-and-kumquat-biosciences-reached-an-e-62065310.html 2021-06-22T14:01:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-nurtec-odt-rimegepant-t-62065311.html 2021-08-31T14:56:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/global-phase-iii-data-of-ivosidenib-combined-w-62065312.html 2021-08-31T14:47:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-progress-has-been-made-in-the-total-synthe-62065313.html 2021-08-31T15:30:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/european-union-approves-astrazeneca-forxig-62065314.html 2021-08-31T15:22:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cabometyx-cabozantinib-has-been-given-priori-62065315.html 2021-08-31T16:27:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/antagonist-sparsentan-phase-3-clinical-effica-62065316.html 2021-09-13T16:48:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-tcr-therapy-tebentafusp-treatment-of-uvea-62065317.html 2021-08-31T16:24:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eisai-launches-tazverik-in-the-japanese-market-62065318.html 2021-08-31T17:07:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-approved-the-new-indication-for-j-62065319.html 2021-09-26T12:57:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-folr-targeted-antibody-c-62065320.html 2021-09-16T17:44:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-fcrn-antagonist-efgartigimod-is-under-revi-62065324.html 2021-08-31T15:33:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-inhibitor-ritlecitinib-phase-2-3-study-62065325.html 2021-09-16T17:56:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jardiance-empagliflozin-the-first-drug-to-s-62065326.html 2021-09-17T17:31:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-beigene-brukinsa-zanubrut-62065327.html 2021-09-17T17:28:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-beigene-brukinsa-zanubrut-62065328.html 2021-07-27T10:53:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/xarelto-rivaroxaban-application-submitted-in-62065329.html 2021-07-27T11:07:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bjp-insights-into-the-mechanisms-and-potentia-62065330.html 2021-07-27T10:58:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tirzepatide-the-effect-of-reducing-blood-suga-62065331.html 2021-07-27T16:05:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-second-generation-parp-inhibitor-62065332.html 2021-08-31T14:59:30+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/scientists-find-that-transglutaminase-2-inhibi-62065333.html 2021-07-30T10:27:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ipsen-has-obtained-mesdopetam-a-new-dopamine-62065334.html 2021-09-17T17:38:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-requires-jak-inhibitors-to-add-black-box-w-62065335.html 2021-06-25T17:44:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-pharmaceuticals-and-pfizer-cooperate-to-62065336.html 2021-09-24T17:27:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/journal-of-medicinal-chemistry-discovery-of-o-62065337.html 2021-07-27T15:22:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rinvoq-upadacitinib-phase-3-maintenance-stud-62065338.html 2021-07-30T11:27:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-rinvoq-s-application-for-new-indication-62065339.html 2021-07-27T14:27:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/lenacapavir-gs-6207-submits-a-listing-applic-62065340.html 2021-09-17T17:36:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-united-states-approved-trudhesa-dihydroer-62065341.html 2021-09-24T17:06:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oxbryta-pediatric-indications-dispersible-ta-62065343.html 2021-08-11T12:02:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/develop-a-combination-therapy-of-shp2-inhibito-62066125.html 2021-09-16T17:19:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ono-takeda-immunity-targeting-program-opdivo-62066131.html 2021-09-24T17:02:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/phase-3-clinical-trial-of-dual-endothelin-angi-62066134.html 2021-09-24T16:54:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vutrisiran-in-the-treatment-of-hattr-amyloidos-62066135.html 2021-06-22T12:02:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eu-grants-accelerated-evaluation-of-valrox-tr-62076418.html 2021-06-18T17:53:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rifampin-evaluation-of-its-use-in-acute-perip-62076419.html 2021-07-30T10:44:17+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/valrox-enters-review-in-the-eu-treatment-of-h-62076420.html 2021-07-27T11:04:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/c-type-natriuretic-peptide-analogue-vosoritide-62076421.html 2021-06-22T15:29:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-brexafemme-treatment-of-v-62076422.html 2021-06-29T17:34:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-mersk-s-new-oral-kinase-inhibitor-62076423.html 2021-09-13T17:41:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/inhibitor-tibsovo-treating-patients-with-idh-62076424.html 2021-08-20T18:01:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-arrowhead-s-second-genera-62076426.html 2021-08-31T16:19:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cell-research-developed-a-new-generation-of-h-62076427.html 2021-08-31T16:19:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-refuses-to-approve-new-drug-roxadustat-62076428.html 2021-08-31T17:09:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-approved-the-new-indication-for-j-62076429.html 2021-09-16T17:52:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-atogepant-preventive-treatment-of-paro-62076800.html 2021-06-22T11:35:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-next-generation-drug-beovu-phase-3-m-62076807.html 2021-08-05T10:54:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/skysona-the-first-gene-therapy-to-treat-cereb-62090396.html 2021-09-26T23:47:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-breakthrough-therapy-desi-62090695.html 2021-07-30T11:49:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astellas-prograf-tacrolimus-approved-for-new-62090696.html 2021-07-27T14:50:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eu-approves-opdivo-yervoy-dual-immunotherapy-p-62090697.html 2021-08-05T14:10:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-verquvo-vericiguat-has-been-approved-i-62090698.html 2021-07-30T10:56:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/olumiant-baricitinib-new-indication-applicat-62090699.html 2021-07-30T10:39:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/hutchison-medicine-s-surufatinib-enters-the-re-62090700.html 2021-08-31T15:28:59+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-european-union-approves-astrazeneca-forxig-62090701.html 2021-09-13T17:33:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-approves-cstone-s-precision-treat-62090704.html 2021-07-30T11:41:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/dovato-is-very-effective-and-will-be-launched-62090960.html 2021-08-31T15:11:24+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rongchang-bio-titacept-completes-domestic-phas-62090962.html 2021-06-25T18:00:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cstone-pharmaceuticals-obtains-fda-approval-fo-62091322.html 2021-06-22T15:15:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/kisqali-reported-the-longest-median-overall-su-62091323.html 2021-08-05T10:40:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jiahe-bio-cdk4-6-inhibitor-for-the-treatment-o-62100345.html 2021-08-11T11:37:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/serotonin-inverse-agonist-nuplazid-has-62100351.html 2021-07-27T11:18:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/forxiga-dapagliflozin-is-about-to-be-approve-62100512.html 2021-06-25T17:58:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eprenetapopt-venetoclax-azacitidine-in-the-tre-62101003.html 2021-06-22T11:45:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nefecon-budesonide-applied-for-listing-in-th-62101004.html 2021-09-27T05:17:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/evrenzo-roxadustat-suffered-three-setbacks-62101005.html 2021-09-27T07:45:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-and-regeneron-have-reached-a-coope-62105669.html 2021-09-24T17:13:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sumitomo-pharmaceuticals-xenleta-lefamulin-w-62105673.html 2021-06-22T14:45:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-lybalvi-olanzapine-samido-62105706.html 2021-09-24T16:57:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vutrisiran-in-the-treatment-of-hattr-amyloidos-62106171.html 2021-09-16T17:51:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-atogepant-preventive-treatment-of-paro-62106172.html 2021-09-13T17:38:18+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/rinvoq-was-approved-by-the-european-union-for-62108197.html 2021-09-27T09:17:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vorasidenib-shows-efficacy-progression-free-s-62108435.html 2021-08-11T11:40:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/selective-serotonin-inverse-agonist-nuplazid-h-62119208.html 2021-06-29T17:40:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jardiance-empagliflozin-has-been-approved-fo-62125373.html 2021-06-29T17:43:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-sub-journal-pi3k-inhibitors-are-about-62133972.html 2021-09-27T22:15:51+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/antagonist-sparsentan-phase-3-clinical-effica-62135542.html 2021-09-28T17:15:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/onvansertib-is-effective-in-treating-kras-muta-63405018.html 2021-11-06T08:29:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-nubeqa-darolutamide-phase-3-clinical-t-63405019.html 2021-10-09T14:07:26+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vutrisiran-applied-for-listing-in-the-eu-trea-63405020.html 2021-10-14T11:56:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-fgfr-kinase-inhibitor-balver-63405021.html 2021-11-06T08:29:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/biogen-tecfidera-s-upgraded-version-of-vumerit-63405022.html 2021-11-06T08:29:21+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tecentriq-the-first-cancer-immunotherapy-for-63405023.html 2021-11-06T08:29:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/gilead-yescarta-enters-review-in-the-united-st-63405024.html 2021-10-25T17:06:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tecentriq-the-first-cancer-immunotherapy-for-63405025.html 2021-10-14T15:32:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/brexafemme-launched-in-the-united-states-trea-63405026.html 2021-10-25T16:11:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tavneos-the-first-oral-selective-complement-c-63405027.html 2021-10-25T16:56:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-weekly-growth-hormone-skytrofa-to-be-63405028.html 2021-11-04T16:28:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-eu-chmp-recommends-approval-of-pfizer-s-63405034.html 2021-11-04T17:19:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/verzenio-abemaciclib-new-data-the-first-cdk-63405035.html 2021-11-04T17:15:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/verzenio-abemaciclib-new-data-the-first-cdk-63405037.html 2021-10-26T15:18:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/application-for-clinical-trial-of-lorlatinib-i-63405038.html 2021-09-28T17:18:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/maralixibat-eu-application-for-listing-treatm-63405233.html 2021-10-09T15:33:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-takeda-exkivity-the-first-63405235.html 2021-10-09T15:37:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-inhibitor-rinvoq-upatinib-submitted-a-63405237.html 2021-10-09T15:50:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-beigene-brukinsa-zanubrut-63405238.html 2021-10-14T16:33:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-opzelura-cream-the-first-topi-63405239.html 2021-10-14T16:30:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-opzelura-cream-the-first-topi-63405445.html 2021-11-06T19:50:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-nubeqa-darolutamide-phase-3-clinical-t-63428917.html 2021-11-04T17:26:43+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-local-drug-delivery-system-prv111-for-the-63428918.html 2021-10-09T15:46:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-beigene-brukinsa-zanubrut-63429119.html 2021-09-28T17:14:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/onvansertib-is-effective-in-treating-kras-muta-63429122.html 2021-10-25T16:05:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-livmarli-the-first-drug-t-63429123.html 2021-10-09T14:28:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/axsome-s-new-oral-multi-mechanism-drug-axs-63429196.html 2021-02-05T05:39:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-s-first-drug-finerenone-has-been-given-53946027.html 2021-01-21T11:14:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-indication-of-boehringer-lilly-jardian-54005261.html 2021-03-03T16:51:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/takeda-darvadstrocel-applied-for-listing-in-ja-54920567.html 2021-03-03T16:54:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sanofi-s-new-factor-viii-therapy-efanesoctocog-54920630.html 2021-03-10T11:17:01+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-psoriasis-drug-tapinarof-long-term-drug-ph-54920792.html 2021-02-08T11:09:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nerlynx-neratinib-a-tyrosine-kinase-inhibit-54920793.html 2021-02-08T09:49:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cancer-immunol-res-how-pancreatic-cancer-cell-54920918.html 2021-02-08T09:53:58+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/a-new-generation-of-tyrosine-kinase-inhibitor-54920919.html 2021-02-08T10:42:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-nuclear-export-inhibitor-nexpovio-s-54920923.html 2021-03-03T15:52:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-abbvie-s-botulinum-toxin-b-54921002.html 2021-02-08T11:00:22+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-mc4r-agonist-imcivree-has-a-strong-e-54921003.html 2021-02-08T09:50:35+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-approves-vertex-for-clinical-test-54921319.html 2021-02-23T17:27:53+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-s-keytruda-treatment-of-triple-negative-54921433.html 2021-03-03T15:45:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-approves-pfizer-panzyga-human-immuno-54922506.html 2021-03-03T16:03:12+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-kesimpta-the-first-b-cell-therapy-th-54922509.html 2021-03-03T16:30:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-new-indication-of-beigene-brukinsa-zanubr-54922543.html 2021-03-03T16:33:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/oral-gnrh-receptor-antagonist-relugolix-compou-54922546.html 2021-03-11T19:58:33+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eu-chmp-recommends-and-approves-xcopri-cenoba-54922550.html 2021-02-23T17:25:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bristol-myers-squibb-jak2-inhibitor-inrebic-ap-54922562.html 2021-03-03T16:15:14+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/amgen-s-targeted-anticancer-drug-sotorasib-rec-54922627.html 2021-02-08T10:54:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/tyvaso-dpi-inhaled-treprostinil-is-safe-and-54922697.html 2021-03-10T11:00:27+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/cell-sub-news-discovers-new-drugs-for-effectiv-54922727.html 2021-02-23T17:29:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/plos-genet-ordinary-people-are-naturally-resi-54922847.html 2021-02-23T14:07:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-s-forxiga-dapagliflozin-approved-54922888.html 2021-02-23T17:22:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-spravato-nasal-spray-approve-54922913.html 2021-02-08T10:38:37+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pemazyre-pemigatinib-a-potent-fgfr-kinase-i-54922954.html 2021-02-08T09:45:38+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/amgen-sotorasib-has-strong-efficacy-in-treatin-54922968.html 2021-03-03T16:18:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-novartis-entresto-sacubit-54923009.html 2021-03-11T20:07:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-first-drug-to-treat-acute-hyperammonemia-a-54923017.html 2021-03-10T11:47:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/multi-target-tki-inhibitors-are-recognized-as-54923020.html 2021-11-11T17:11:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/devimistat-cpi-613-failed-in-the-phase-3-cli-64270761.html 2021-11-24T10:37:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-zandelisib-orphan-drug-desi-64270762.html 2021-11-24T10:51:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/inhibitor-rinvoq-upadacitinib-treatment-of-m-64270763.html 2021-11-24T10:23:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bayer-eylea-aflibercept-applied-for-new-indi-64270766.html 2021-11-11T15:20:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/phase-3-clinical-success-of-the-new-long-actin-64286959.html 2021-11-27T04:27:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/ono-pharmaceutical-submits-application-for-new-64286960.html 2021-11-24T10:25:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/emalex-s-first-phase-2b-study-of-dopamine-d1-r-64286961.html 2021-11-24T10:31:32+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-oral-jak-inhibitor-olumiant-baric-64287109.html 2021-11-11T16:25:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/teva-and-modag-reached-an-exclusive-global-lic-64292417.html 2021-11-27T08:36:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/phase-3-clinical-success-of-the-new-long-actin-64292420.html 2021-11-11T17:05:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/otsuka-pharmaceutical-s-hif-ph-inhibitor-vadad-64292421.html 2021-11-27T08:41:54+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/vraylar-carbimazine-adjuvant-treatment-of-md-64292528.html 2021-11-11T15:27:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-xipere-triamcinolone-acet-64296286.html 2021-11-18T11:53:39+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nature-s-first-report-on-obesity-pills-recog-64296351.html 2021-11-24T10:30:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-oral-jak-inhibitor-olumiant-baric-64303048.html 2021-11-27T23:46:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-stamp-inhibitor-scemblix-asci-64309858.html 2021-11-11T16:29:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-kymriah-s-third-indication-enters-rev-64309859.html 2021-11-24T11:33:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/jardiance-empagliflozin-enters-priority-revi-64313613.html 2021-11-11T15:24:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-fast-track-qualification-64318395.html 2021-11-24T10:41:46+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/novartis-amgen-aimovig-head-to-head-phase-4-c-64318988.html 2021-11-18T11:42:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-gip-glp-1-dual-agonist-tirzepatide-64319496.html 2021-12-23T13:53:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/beigene-s-tyk2-inhibitor-bgb-23339-enters-phas-65532531.html 2021-12-23T14:48:16+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-u-s-fda-granted-ctx110-regenerative-medic-65532533.html 2021-12-09T14:58:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pioneering-sirna-cholesterol-lowering-drug-leq-65532647.html 2021-12-09T14:56:45+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pioneering-sirna-cholesterol-lowering-drug-leq-65532648.html 2021-12-09T17:11:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-granted-the-zn-c3-fast-track-qualif-65532649.html 2021-12-09T16:58:44+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/astrazeneca-modena-azd8601-phase-2-study-nt-p-65532650.html 2021-12-09T16:03:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sglt1-2-inhibitor-zynquista-sotagliflozin-s-65532651.html 2021-12-23T17:23:42+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/abbvie-vuity-pilocarpine-1-25-is-launched-i-65532653.html 2021-12-09T17:03:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-granted-astrazeneca-lokelma-sodium-z-65582647.html 2021-12-09T17:09:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/paclitaxel-liposomes-have-outstanding-performa-65582837.html 2021-12-23T15:42:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/u-s-fda-granted-arfolitixorin-fast-track-qual-65598724.html 2021-12-09T17:16:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-european-union-approves-the-fifth-indicati-65598725.html 2022-01-02T01:27:09+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-antagonist-yselty-linzagolix-is-under-re-65605192.html 2021-12-09T15:51:28+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sglt1-2-inhibitor-zynquista-sotagliflozin-s-65605195.html 2021-12-23T13:40:00+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/bluebird-bio-zynteglo-receives-priority-review-65605285.html 2021-12-23T17:24:50+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/reblozyl-applies-for-expanded-indications-in-t-65605287.html 2021-12-23T12:06:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-european-union-approves-qinlock-ripretini-65610509.html 2021-12-09T15:04:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-eu-approves-a-new-indication-for-oral-jak-65612624.html 2022-01-06T16:00:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-caplyta-lumateperone-th-66417557.html 2022-01-13T14:16:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fintepla-fenfluramine-applied-for-a-new-indi-66417558.html 2022-01-21T10:15:03+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eu-approves-wegovy-semaglutide-18-weight-66417559.html 2021-11-06T08:29:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/axsome-s-new-oral-multi-mechanism-drug-axs-63405029.html 2021-10-26T15:03:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-new-generation-oral-jak1-inhibitor-ci-63405031.html 2021-11-06T08:29:20+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/results-of-phase-ii-study-of-fgfr-inhibitors-i-63405032.html 2021-10-25T16:17:29+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/merck-keytruda-successfully-treats-asian-hcc-p-63428916.html 2021-11-04T17:32:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-tyrosine-kinase-inhibitor-cabometyx-caboz-63439494.html 2021-10-14T11:54:07+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/johnson-johnson-fgfr-kinase-inhibitor-balver-63439497.html 2021-11-07T01:56:25+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approves-takeda-exkivity-the-first-63439499.html 2021-11-04T16:32:41+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/emopamil-binding-protein-ebp-inhibitor-dsp-63439668.html 2021-10-26T15:05:56+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pfizer-s-new-generation-oral-jak1-inhibitor-ci-63445176.html 2021-10-14T11:50:40+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nice-recommends-orladeyo-for-preventive-treatm-63445260.html 2021-11-07T05:46:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/the-us-fda-approved-livmarli-the-first-drug-t-63448319.html 2021-10-14T15:30:48+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/brexafemme-launched-in-the-united-states-trea-63448326.html 2021-11-11T15:33:34+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/two-phase-3-clinical-successes-of-doravirine-i-64270759.html 2021-11-11T16:20:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/non-invasive-skin-patch-viaskin-peanut-dbv-64270760.html 2022-01-21T10:01:15+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/chi-med-s-hmpl-523-is-included-in-the-breakthr-66544379.html 2022-01-13T14:13:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/eli-lilly-s-pirtobrutinib-shows-strong-efficac-66544575.html 2022-01-13T14:10:19+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/shionogi-redasemtide-s-005151-in-the-treatme-66544769.html 2022-01-13T14:19:47+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/pivotal-clinical-trial-application-for-lorlati-66610632.html 2022-01-06T16:08:06+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nuplazid-a-selective-serotonin-inverse-agonis-66610747.html 2024-08-23T17:42:49+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/excess-damage-for-health-preservation-100235612.html 2022-01-21T10:20:04+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/us-fda-approves-new-indication-of-jak1-inhibit-66619938.html 2022-01-06T15:55:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/nubeqa-darolutamide-phase-3-clinical-success-66619940.html 2022-01-06T15:36:05+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/kerendia-finerenone-is-about-to-be-approved-66768519.html 2022-01-06T17:01:57+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/fda-approved-xarelto-rivaroxaban-for-2-pedia-66723252.html 2024-08-02T16:24:13+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/new-era-natural-health-exercise-health-treasur-98877566.html 2024-08-22T13:55:55+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/emotional-health-model-100235607.html 2024-08-28T18:51:10+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/supplement-deficiencies-for-health-preservatio-100235608.html 2024-08-26T18:57:36+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/mingyue-sunshine-health-preservation-100235609.html 2024-09-02T17:54:08+08:00 weekly 0.8 https://fi.hsp-pharma.com/info/sleep-aid-and-light-health-preservation-100235610.html